<SEC-DOCUMENT>0001193125-18-128933.txt : 20180424
<SEC-HEADER>0001193125-18-128933.hdr.sgml : 20180424
<ACCEPTANCE-DATETIME>20180424165557
ACCESSION NUMBER:		0001193125-18-128933
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20180424
DATE AS OF CHANGE:		20180424

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SANGAMO THERAPEUTICS, INC
		CENTRAL INDEX KEY:			0001001233
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				680359556
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-224418
		FILM NUMBER:		18771969

	BUSINESS ADDRESS:	
		STREET 1:		501 CANAL BLVD
		STREET 2:		POINT RICHMOND TECH CNTR.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94804
		BUSINESS PHONE:		5109706000

	MAIL ADDRESS:	
		STREET 1:		501 CANAL BLVD
		STREET 2:		POINT RICHMOND TECH CNTR.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94804

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANGAMO BIOSCIENCES INC
		DATE OF NAME CHANGE:	20000208
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d570679d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed pursuant to Rule 424(b)(5)<BR>Registration No. 333-224418 </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#ff4338"><B>The information in this preliminary prospectus supplement is not
complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any state where the offer or sale is not
permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>Subject to
completion, dated April 24, 2018 </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preliminary Prospectus Supplement </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(To Prospectus dated April&nbsp;24, 2018) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$200,000,000 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g570679g76n76.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are offering $200,000,000 of
shares of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The Nasdaq Global Select Market under the symbol &#147;SGMO.&#148; On April&nbsp;23, 2018, the
last reported sale price of our common stock as reported on The Nasdaq Global Select Market was $18.15 per share. Based on an assumed public offering price of $18.15 per share, the last reported sale price of our common stock on The Nasdaq Global
Select Market on April&nbsp;23, 2018, we would expect to offer approximately 11,019,284 shares hereby. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and
commissions<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds to Sangamo Therapeutics, before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">See the section entitled &#147;Underwriting&#148; for additional disclosure regarding underwriter compensation and estimated offering expenses. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have granted the underwriters an option for a period of 30 days to purchase up to $30,000,000 of additional shares of our common stock, solely to cover
overallotments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman"><B>Investing in our common stock involves a high degree of risk. See <A HREF="#supprom570679_3">&#147;Risk
Factors&#148;</A> beginning on page&nbsp;S-13 of this prospectus supplement and in the Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the Securities and Exchange Commission on April&nbsp;17, 2018, as well as our other
filings that are incorporated by reference into this prospectus supplement and the accompanying prospectus. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange
Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal
offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gilead Sciences, Inc. has indicated an interest in purchasing up to approximately $50,000,000 of the shares of common stock offered hereby at the price
offered to the public. Because this indication of interest is not a binding agreement or commitment to purchase, this entity may elect not to purchase any shares in this offering, or the underwriters may elect not to sell any shares in this offering
to it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters expect to deliver the shares to purchasers on or about April &nbsp;&nbsp;&nbsp;&nbsp;, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Joint Book-Running Managers </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:14pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:14pt">
<TD VALIGN="top"><B>BofA&nbsp;Merrill&nbsp;Lynch</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>J.P.&nbsp;Morgan</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Cowen</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>April &nbsp;&nbsp;&nbsp;&nbsp;, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center"><B>Prospectus Supplement</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom570679_1">About this Prospectus Supplement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-ii</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom570679_2">Prospectus Supplement Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom570679_3">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-13</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom570679_4">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-17</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom570679_5">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-19</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom570679_6">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-19</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom570679_7">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-20</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom570679_8">Price Range of Common Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-22</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom570679_9">Material U.S. Federal Income Tax Consequences for <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders of Common Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-23</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom570679_10">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-27</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom570679_11">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-34</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom570679_12">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-34</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom570679_13">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-34</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom570679_14">Incorporation of Certain Information by Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-34</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center"><B>Prospectus</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc573964_1">About this Prospectus</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc573964_2">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc573964_3">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc573964_4">Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc573964_5">Financial Ratios</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc573964_6">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc573964_7">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc573964_8">Description of Debt Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc573964_9">Description of Warrants</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc573964_10">Legal Ownership of Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc573964_11">Selling Securityholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc573964_12">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc573964_13">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc573964_14">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc573964_15">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc573964_16">Incorporation of Certain Information by Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-i </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>We have not, and the underwriters have not, authorized anyone to provide you with
information different than or inconsistent with the information contained in or incorporated by reference in this prospectus supplement, the accompanying prospectus and in any free writing prospectus that we have authorized for use in connection
with this offering. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We are not, and the underwriters are not, making an offer to sell these
securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus supplement, the accompanying prospectus, the documents incorporated by reference in this prospectus
supplement and the accompanying prospectus, and in any free writing prospectus that we have authorized for use in connection with this offering, is accurate only as of the date of those respective documents, regardless of the time of delivery of
those respective documents. Our business, financial condition, results of operations and prospects may have changed since those dates. You should read this prospectus supplement, the accompanying prospectus, the documents incorporated by reference
in this prospectus supplement and the accompanying prospectus, and any free writing prospectus that we have authorized for use in connection with this offering, in their entirety before making an investment decision. You should also read and
consider the information in the documents to which we have referred you in the sections of this prospectus supplement entitled &#147;Where You Can Find More Information&#148; and &#147;Incorporation of Certain Information by Reference.&#148;
</B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom570679_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document is in two parts. The first part is this prospectus supplement, which describes the terms of this offering of common stock and
also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into this prospectus supplement and the accompanying prospectus. The second part, the accompanying prospectus dated
April&nbsp;24, 2018, including the documents incorporated by reference therein, provides more general information. Generally, when we refer to this prospectus, we are referring to both parts of this document combined. To the extent there is a
conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or in any document incorporated by reference that was filed with the Securities and Exchange
Commission, or SEC, before the date of this prospectus supplement, on the other hand, you should rely on the information in this prospectus supplement. If any statement in one of these documents is inconsistent with a statement in another document
having a later date &#151; for example, a document incorporated by reference in the accompanying prospectus &#151; the statement in the document having the later date modifies or supersedes the earlier statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All references in this prospectus supplement and the accompanying prospectus to &#147;Sangamo,&#148; &#147;the Company,&#148; &#147;we,&#148;
&#147;us,&#148; &#147;our,&#148; or similar references refer to Sangamo Therapeutics,&nbsp;Inc., a Delaware corporation, and its subsidiaries on a consolidated basis, except where the context otherwise requires or as otherwise indicated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement, the accompanying prospectus, and the information incorporated herein and therein by reference include trademarks,
trade names and service marks owned by us or other companies. SANGAMO<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, SANGAMO THERAPEUTICS<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Better Therapeutics By Design<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, ZFP Therapeutic<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Engineering Genetic Cures<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, and Pioneering Genetic Cures<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> are our registered trademarks in the United States. All other trademarks or trade names referred to in this prospectus supplement, the accompanying prospectus and the information incorporated
herein and therein by reference are the property of their respective owners. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-ii </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom570679_2"></A>PROSPECTUS SUPPLEMENT SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights certain information about us, this offering and selected information contained elsewhere in or incorporated by
reference into this prospectus supplement. This summary is not complete and does not contain all of the information that you should consider before deciding whether to invest in our common stock. For a more complete understanding of our company and
this offering, you should read and consider carefully the more detailed information included or incorporated by reference in this prospectus supplement and the accompanying prospectus, including the factors described under the heading &#147;Risk
Factors&#148; of this prospectus supplement, in our Current Report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> filed with the SEC on April&nbsp;17, 2018 and in our other filings that are incorporated by reference into this prospectus
supplement and the accompanying prospectus, as well as the information included in any free writing prospectus that we have authorized for use in connection with this offering. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical stage
biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients&#146; lives using our industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. We
have used our knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA
sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, we
have accrued significant scientific, manufacturing and regulatory capabilities and <FONT STYLE="white-space:nowrap">know-how</FONT> that are generally applicable in the broader field of gene therapy and have capitalized this knowledge into a
conventional gene therapy platform based on adeno-associated viral vector, or AAV, cDNA gene transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our strategy is to maximize the
value and therapeutic use of our technology platforms. In certain therapeutic areas we intend to capture the value of our proprietary genome editing and gene therapy products by forward integrating into manufacturing, development and commercial
operations. In other therapeutic areas we intend to partner with biopharmaceutical companies to develop products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are focused on the
development of human therapeutics for diverse diseases with well-characterized genetic causes. We have several proprietary clinical and preclinical product candidates in development and have strategically partnered certain programs with
biopharmaceutical companies to obtain funding for our own programs and to expedite clinical and commercial development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have an
ongoing Phase 1/2 clinical trial evaluating <FONT STYLE="white-space:nowrap">SB-525,</FONT> a gene therapy for the treatment of hemophilia A, a bleeding disorder. We also have ongoing Phase 1/2 clinical trials evaluating three product candidates
using our&nbsp;proprietary <I>in vivo</I>&nbsp;genome editing approach: <FONT STYLE="white-space:nowrap">SB-FIX</FONT> for the treatment of hemophilia B, a bleeding disorder; <FONT STYLE="white-space:nowrap">SB-318,</FONT> for the treatment of
Mucopolysaccharidosis Type I, or MPS I; and <FONT STYLE="white-space:nowrap">SB-913</FONT> for the treatment of Mucopolysaccharidosis Type II, or MPS II. MPS I and MPS II are rare lysosomal storage disorders, or LSDs.&nbsp;We are also initiating a
Phase 1/2 clinical trial evaluating <FONT STYLE="white-space:nowrap">ST-400,</FONT> developed using our proprietary <FONT STYLE="white-space:nowrap">ZFN-mediated</FONT> <I>ex vivo</I> cell therapy platform, for the&nbsp;treatment of
beta-thalassemia, a blood disorder. In addition, we have proprietary preclinical and discovery stage programs in other LSDs, hematological disorders and monogenic diseases, including certain central nervous system, or CNS, disorders, cancer
immunotherapy, immunology and infectious disease. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2018, we entered into a global collaboration and license agreement with Kite
Pharma, Inc., or Kite, a wholly owned subsidiary of Gilead Sciences, Inc., or Gilead, for the research, development and commercialization of potential engineered cell therapies for cancer. In this collaboration, we will work together with Kite on a
research program under which we will design ZFNs and AAVs to disrupt and insert certain genes in T cells and natural killer, or NK, cells, including the insertion of genes that encode chimeric antigen receptors, or CARs, <FONT
STYLE="white-space:nowrap">T-cell</FONT> receptors, or TCRs and <FONT STYLE="white-space:nowrap">NK-cell</FONT> receptors, or NKRs, directed to mutually agreed targets. Kite will be responsible for all clinical development and commercialization of
any resulting products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2017, we entered into a new research collaboration and license agreement with Pfizer Inc., or Pfizer,
for the development and commercialization of potential gene therapy products that use ZFP TFs to treat amyotrophic lateral sclerosis, or ALS, and frontotemporal lobar degeneration, or FTLD, linked to mutations of the <I>C9ORF72</I> gene. Under this
agreement, we are working with Pfizer on a research program to identify, characterize and preclinically develop ZFP TFs that satisfy <FONT STYLE="white-space:nowrap">pre-agreed</FONT> criteria. Pfizer is responsible for subsequent development,
manufacturing and commercialization of licensed products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2017, we entered into a global collaboration and license agreement with
Pfizer for the research, development and commercialization of <FONT STYLE="white-space:nowrap">SB-525,</FONT> our gene therapy product candidate for hemophilia A, and closely related products. Under this agreement, we are responsible for conducting
the Phase 1/2 clinical trial and certain manufacturing activities for <FONT STYLE="white-space:nowrap">SB-525,</FONT> while Pfizer is responsible for subsequent worldwide development, manufacturing, marketing and commercialization of <FONT
STYLE="white-space:nowrap">SB-525.</FONT> We and Pfizer may also collaborate in the research and development of additional <FONT STYLE="white-space:nowrap">AAV-based</FONT> gene therapy products for hemophilia A. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have also established a collaborative partnership with Bioverativ, Inc., or Bioverativ, a wholly owned subsidiary of Sanofi, to research,
develop and commercialize therapeutic gene-edited cell therapy products in hemoglobinopathies, including beta-thalassemia and sickle cell disease, or SCD. We expect to begin enrolling patients in a Phase 1/2 clinical study for beta-thalassemia in
the first half of 2018. Bioverativ is responsible for subsequent development, manufacturing and commercialization of licensed products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a substantial intellectual property position in the genome editing field including the design, selection, composition and use of
engineered ZFPs to support our research and development activities. As of February&nbsp;15, 2018, we either owned outright or have exclusively licensed the commercial rights to over 860 patents issued in the United States and foreign jurisdictions,
and over 610 patent applications pending worldwide. We continue to license and file new patent applications that strengthen our core and accessory patent portfolio. We believe that our intellectual property position is a critical element in our
ability to research,&nbsp;develop and commercialize products and services based on genome editing, gene therapy, gene regulation and cell therapy. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Product Development </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g570679g13d40.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Hemophilia A and B </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Hemophilia is a rare bleeding disorder in which the blood does not clot normally. It is also a monogenic disease, or a disease that is caused
by a genetic defect in a single gene. There are several types of hemophilia caused by mutations in genes that encode factors which help the blood clot and stop bleeding when blood vessels are injured. Individuals with hemophilia experience bleeding
episodes after injuries and spontaneous bleeding episodes that often lead to joint disease such as arthritis. The most severe forms of hemophilia affect males. The standard treatment for individuals with hemophilia is replacement of the defective
clotting factor with regular infusion of recombinant clotting factors or plasma concentrates. These therapies are expensive and sometimes stimulate the body to produce antibodies against the factors that inhibit the benefits of treatment. In these
situations, other clotting factors such as Factor VII and X may be used to treat patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The most prevalent form of the disease,
hemophilia A, is caused by a defect in the clotting Factor 8 gene. According to the National Hemophilia Foundation and the World Federation of Hemophilia, hemophilia A occurs in about one in every 5,000 male births in the United States, with
approximately 16,000 males currently affected. Defects in clotting Factor 9 gene lead to hemophilia B. Hemophilia B occurs in about one in every 25,000 male births in the United States, with approximately 4,000 males currently affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">SB-525</FONT> &#151; Hemophilia A </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <FONT STYLE="white-space:nowrap">SB-525,</FONT> a gene therapy product candidate utilizing an AAV carrying a clotting Factor
8 gene construct that is driven by our proprietary synthetic liver specific promoter. In 2016, we presented preclinical data demonstrating production of supraphysiological levels of human Factor VIII clotting protein, or hFVIII, in mice and <FONT
STYLE="white-space:nowrap">non-human</FONT> primates, or NHPs. In these dose-ranging preclinical studies, mean hFVIII levels of 5 &#151; 230% of normal were observed using AAV doses in the range of 6.00E+11 &#151; 6.00E+12 vg/kg, the most potent
dose response reported in NHPs for a human Factor 8 gene construct at the time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2017, we initiated a Phase 1/2 clinical trial, the
Alta Study, to evaluate the safety and efficacy of <FONT STYLE="white-space:nowrap">SB-525</FONT> in adults with severe hemophilia A. The Alta Study is an open-label, ascending-dose study designed to enroll up
</P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to 20 adult subjects across six potential dose cohorts. In August 2017, we announced that the first subject was treated in our Alta Study. Currently, there are four patients dosed with <FONT
STYLE="white-space:nowrap">SB-525.</FONT> We expect to release preliminary data from the Alta Study in the third quarter of 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">SB-525</FONT> has been granted Orphan Drug and Fast Track designations by the U.S. Food and Drug Administration, or FDA, as well as Orphan Medicinal Product designation by the European Medicines Agency, or EMA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">SB-FIX</FONT> &#151; Hemophilia B </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <FONT STYLE="white-space:nowrap">SB-FIX,</FONT> an <I>in vivo</I> genome editing product candidate, to treat hemophilia B.
Utilizing our ZFN genome editing technology, we are adding a new therapeutic copy of the Factor 9 gene precisely into the Albumin gene locus in liver cells, and using the strong endogenous Albumin promoter to drive expression of the newly inserted
gene. We believe the potential of this approach to provide a permanent correction for a patient may be optimal for a pediatric population by reducing or eliminating the need for chronic infusions of replacement proteins or clotting factor products.
We have published data demonstrating the potential utility of this approach for several different monogenic disease applications in addition to hemophilia B. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preclinical studies of the Albumin genome editing approach have demonstrated that therapeutic levels of Factor IX clotting protein could be
generated in a dose-dependent manner in NHPs. There were no significant alterations in circulating Albumin levels. Studies in mice also demonstrated stable Factor IX production for over one year. Preclinical studies in wildtype mice have
demonstrated expression of therapeutic levels of human clotting Factor IX protein, or hFIX, from the liver and into the blood for the duration of the <FONT STYLE="white-space:nowrap">60-week</FONT> study. Additional preclinical studies in mouse
models of hemophilia B demonstrated expression of therapeutic levels of hFIX from the liver and into the blood, which resulted in the correction of the clotting defect in hemophilia B mice treated with a single dose of
<FONT STYLE="white-space:nowrap">SB-FIX.</FONT> <FONT STYLE="white-space:nowrap">SB-FIX</FONT> was also evaluated in preclinical NHP studies and demonstrated dose-dependent, therapeutic levels of hFIX expression, between <FONT
STYLE="white-space:nowrap">20-50%</FONT> of normal, in wildtype cynomolgus monkeys, after a single administration of <FONT STYLE="white-space:nowrap">SB-FIX.</FONT> Levels of hFIX were stable for up to three months in treated NHPs. Furthermore,
there was a strong dose-response correlation between the level of gene modification at the Albumin locus and the levels of hFIX measured in the blood. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2016, we initiated a Phase 1/2, open-label, ascending dose clinical trial, the FIXtendz Study, to evaluate safety and efficacy of <FONT
STYLE="white-space:nowrap">SB-FIX</FONT> in adult males with severe hemophilia B. The FIXtendz Study is designed to enroll up to 12 subjects across three dose cohorts. In February 2018, the Medicines and Healthcare Products Regulatory Agency, or
MHRA, of the United Kingdom granted Clinical Trial Authorisation, or CTA, for enrollment of subjects into the ongoing Phase 1/2 clinical trial evaluating <FONT STYLE="white-space:nowrap">SB-FIX</FONT> for hemophilia B. The CTA permits evaluation of <FONT
STYLE="white-space:nowrap">SB-FIX</FONT> in both adults and adolescents. We expect to open clinical trial sites in the United Kingdom in the second half of 2018. Once preliminary safety has been demonstrated in the ongoing <FONT
STYLE="white-space:nowrap">SB-FIX</FONT> Phase 1/2 clinical trial in adults (18 years of older), we may begin enrolling adolescents (12&nbsp;&#150;&nbsp;17 years of age) into the study. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SB-FIX</FONT> has been granted Orphan Drug and Fast Track designations by the FDA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Lysosomal Storage Disorders </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">LSDs
are a heterogeneous group of rare inherited metabolic disorders including: MPS I, MPS II, Fabry disease, Gaucher disease and many others. These disorders are caused by defects in genes that encode proteins known as enzymes, which break down and
eliminate unwanted substances in cells. These enzymes are found in structures called lysosomes which act as recycling sites in cells, breaking down unwanted material into simple products. A defect in a lysosomal enzyme leads to the accumulation of
toxic levels of the substance that the enzyme would normally eliminate. These toxic levels may cause cell damage which can lead to serious health problems. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MPS I is caused by mutations in the gene encoding the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">alpha-L-iduronidase,</FONT></FONT> or IDUA, enzyme, resulting in a deficiency of IDUA enzyme, which is required for the degradation of the glycosaminoglycans, or GAGs, dermatan sulfate and heparin sulfate. The inability to
degrade GAGs leads to their accumulation within the lysosomes throughout the body. Individuals with this mutation experience multi-organ dysfunction and damage. Depending on the severity of the mutations and degree of residual enzyme activity,
affected individuals may develop enlarged internal organs, joint stiffness, skeletal deformities, corneal clouding, hearing loss and cognition impairments. Three forms of MPS I, in order of increasing severity, include Scheie, Hurler-Scheie and
Hurler syndromes. According to the National MPS Society, one in 500,000 births in the United States will result in Scheie syndrome, one in 115,000 births in Hurler/Scheie, and one in 100,000 births results in Hurler syndrome. There are approximately
1,000 MPS I patients in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MPS II is an <FONT STYLE="white-space:nowrap">X-linked</FONT> disorder primarily affecting
males and caused by mutations in the gene encoding the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">iduronate-2-sulfatase,</FONT></FONT> or IDS, enzyme. This results in a deficiency of IDS enzyme, which is required for the
degradation of GAGs. Similar to MPS I, the inability to degrade GAGs leads to their accumulation within the lysosomes throughout the body. Individuals with this mutation experience multi-organ dysfunction and damage. Children with MPS II appear
normal at birth but begin showing symptoms of developmental delay by age&nbsp;2&nbsp;&#150;3&nbsp;years. Depending on the severity of the mutations and degree of residual enzyme activity, affected individuals may develop delayed development,
enlarged internal organs, cardiovascular disorders, stunted growth and skeletal abnormalities and hearing loss. The disorder is progressive and symptoms range from mild (normal cognitive function) to severe (cognitively impaired). According to the
National MPS Society, one in 100,000 male births in the United States will result in MPS II. There are approximately 500 MPS II patients in the United&nbsp;States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fabry disease is an <FONT STYLE="white-space:nowrap">X-linked</FONT> disorder primarily affecting males and caused by a mutation in the gene
encoding the alpha-galactosidase A, or <FONT STYLE="white-space:nowrap">alpha-Gal</FONT> A, enzyme, resulting in a deficiency of <FONT STYLE="white-space:nowrap">alpha-Gal</FONT> A enzyme, which is required for the degradation of the ganglioside
globotriaosylceramide, a particular type of fatty substance. The inability to degrade this fatty substance leads to its accumulation within the lysosomes throughout the body. Individuals with this mutation experience multi-organ dysfunction and
damage. Depending on the severity of the mutations and degree of residual enzyme activity, affected individuals may develop progressive kidney damage, heart attack, stroke, gastrointestinal complications, corneal opacity, tinnitus and hearing loss.
Milder forms of the disorder present later in life and affect only the heart or kidneys. According to the National Institutes of Health U.S. National Library of Medicine, one in 40,000 to one in 60,000 male births in the United States will result in
Fabry disease. There are approximately 2,200 males with Fabry disease in the United States. This mutation can also occur in females, however is less common and the frequency is unknown. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are limited treatments currently available for MPS I, MPS II and Fabry disease. For individuals with MPS I, there are only two options:
hematopoietic stem cell transplantation, or HSCT, for those with the most severe form of the disease (Hurler) and enzyme replacement therapy, or ERT, for patients with the attenuated forms of the disease (Hurler-Scheie, Scheie). However, the
reported mortality rate after HSCT is approximately 15% and the survival rate with successful engraftment is 56%. Most patients with milder forms of the disease receive weekly ERT, usually in a doctor&#146;s office. These IDUA enzyme infusions take
on average four to six hours to administer. Weekly and <FONT STYLE="white-space:nowrap">bi-weekly</FONT> ERT infusions are the only available options for MPS II and Fabry disease, respectively. Because of the availability of few treatment options
that effectively and safely treat these diseases, there remains significant unmet medical need. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">SB-913</FONT> &#151; MPS II </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <FONT STYLE="white-space:nowrap">SB-913,</FONT> an <I>in vivo </I>genome editing product candidate, to treat MPS II. Similar
to <FONT STYLE="white-space:nowrap">SB-318,</FONT> we are using our ZFN genome editing technology to add a new therapeutic copy of the IDS gene precisely into the <I>Albumin</I> gene locus in the genome of liver cells, using the strong endogenous
Albumin promoter to drive expression of the newly inserted gene. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preclinical mouse model data demonstrated robust levels of IDS enzyme expression in the
liver, blood plasma and spleen of <FONT STYLE="white-space:nowrap">SB-913</FONT> treated mice, resulting in a <FONT STYLE="white-space:nowrap">100-fold</FONT> increase in IDS activity, with sustained elevated levels in the blood plasma over the
course of the entire study. Additional preclinical mouse model data demonstrated stable production of therapeutic levels of IDS enzyme from the liver into the circulation and additional secondary tissues, including the spleen, lung, muscle, heart
and brain, after a single intravenous administration of <FONT STYLE="white-space:nowrap">SB-913.</FONT> This resulted in the significant reduction of GAG biomarkers across all the tissues. Behavioral data from Barnes maze tests, collected at the end
of the four-month study demonstrated statistically significant preservation of cognitive learning and memory in mice treated with <FONT STYLE="white-space:nowrap">SB-913,</FONT> compared to untreated mice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2017, we initiated an open-label, dose-ascending Phase 1/2 clinical trial, the CHAMPIONS Study, to evaluate the safety and efficacy of <FONT
STYLE="white-space:nowrap">SB-913</FONT> in adult male subjects with attenuated MPS II, designed to enroll up to nine subjects across three ascending dose cohorts. In November 2017, we announced that the first subject had been treated in the
CHAMPIONS Study. In February 2018, we presented preliminary <FONT STYLE="white-space:nowrap">six-week</FONT> safety data from the first subject enrolled in the CHAMPIONS Study. The data demonstrated that the subject tolerated the infusion well. Mild
(Grade 1) adverse events related to the study drug were reported on the fourth day after dosing. These were dizziness, weakness and frequent urination, all of which resolved within one day without treatment. No other adverse events related to the
study drug have been observed. Liver function tests have remained within normal limits for the patient since the infusion. Currently, there are four patients dosed with <FONT STYLE="white-space:nowrap">SB-913.</FONT> We expect to present additional
safety and preliminary efficacy data from the CHAMPIONS Study in the third quarter of 2018. We submitted a CTA in the first half of 2018 to initiate enrollment of adolescent and pediatric subjects in the United Kingdom into the Phase 1/2 clinical
trial. We expect to open clinical trial sites in the United Kingdom in the second half of 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SB-913</FONT> has been granted Orphan Drug, Rare Pediatric Disease and Fast Track designations by the FDA, as
well as Orphan Medicinal Product designation by the EMA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">SB-318</FONT> &#151; MPS I </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <FONT STYLE="white-space:nowrap">SB-318,</FONT> an <I>in vivo</I> genome editing product candidate, to treat MPS I. Using the
same approach as our hemophilia B product candidate, <FONT STYLE="white-space:nowrap">SB-FIX,</FONT> we are adding a new therapeutic copy of the IDUA gene precisely into the <I>Albumin</I> gene locus in the genome of liver cells, using the strong
endogenous Albumin promoter to drive expression of the newly inserted gene. We believe the potential of this approach to provide a permanent correction for a patient may be optimal for a pediatric population by reducing or eliminating the need for
chronic ERT infusions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preclinical mouse model data demonstrated robust levels of IDUA enzyme expression in the liver, blood plasma and
spleen of <FONT STYLE="white-space:nowrap">SB-318</FONT> treated mice, resulting in a <FONT STYLE="white-space:nowrap">10-fold</FONT> increase in IDUA activity, with sustained elevated levels in the blood plasma over the course of the <FONT
STYLE="white-space:nowrap">two-month</FONT> study. Additional preclinical mouse model data demonstrated stable production of therapeutic levels of IDUA enzyme from the liver into the circulation and secondary tissues, including the spleen, lung,
muscle, heart and brain, after a single intravenous administration of <FONT STYLE="white-space:nowrap">SB-318.</FONT> This resulted in the significant reduction of GAG biomarkers in all of the tissues. Behavioral data from Barnes maze tests,
collected at the end of the four-month study, demonstrated statistically significant preservation of cognitive learning and memory in mice treated with <FONT STYLE="white-space:nowrap">SB-318,</FONT> compared to untreated mice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2017, we initiated an open-label, dose-ascending Phase 1/2 clinical trial, the EMPOWERS Study, to evaluate
<FONT STYLE="white-space:nowrap">SB-318</FONT> in adult subjects with attenuated MPS I. The EMPOWERS Study is designed to enroll up to nine subjects across three ascending dose cohorts. Based on the preliminary safety data from the CHAMPIONS Study
discussed above, in April 2018, we amended the protocol for the EMPOWERS Study so that the patients would initiate treatment in the study at the <FONT STYLE="white-space:nowrap">mid-dose</FONT> level. We expect to present preliminary safety and
efficacy </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
data from the EMPOWERS Study in 2018. We submitted a CTA to initiate enrollment of adolescent and pediatric subjects in the United Kingdom into the Phase 1/2 clinical trial. We expect to open
clinical trial sites in the United Kingdom in the second half of 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SB-318</FONT> MPS I has been
granted Orphan Drug, Rare Pediatric Disease and Fast Track designations by the FDA, as well as Orphan Medicinal Product designation by the EMA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">ST-920</FONT> &#151; Fabry Disease </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <FONT STYLE="white-space:nowrap">ST-920</FONT> for Fabry disease. <FONT STYLE="white-space:nowrap">ST-920</FONT> is a gene
therapy product candidate utilizing an AAV, carrying a galactosidase alpha, or GLA, gene construct, coding for the <FONT STYLE="white-space:nowrap">alpha-Gal</FONT> A enzyme, driven by our proprietary synthetic liver specific promoter. We are
currently conducting <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies for <FONT STYLE="white-space:nowrap">ST-920</FONT> and expect to file an IND application with the FDA in 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Hemoglobinopathies: Beta-thalassemia and Sickle Cell Disease </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mutations in the gene encoding beta-globin, the oxygen carrying protein of red blood cells, lead to hemoglobinopathies such as beta-thalassemia
and sickle cell disease, or SCD. Both diseases manifest in the months after birth, when patients switch from producing functional fetal gamma-globin to a mutant form of adult beta-globin, which results in their condition. Naturally occurring
increased levels of fetal hemoglobin have been shown to reduce the severity of both beta-thalassemia and SCD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beta-thalassemia is a rare
disorder that results in greatly impaired production of healthy red blood cells despite bone marrow over activity, leading to life-threatening anemia, enlarged spleen, liver and heart, and bone abnormalities. We are focused on Beta-thalassemia major
which is a severe form of thalassemia that requires regular, often monthly, blood transfusions and subsequent iron-chelation therapy to treat iron overload. The Centers for Disease Control and Prevention, or CDC, estimates that 1,000 people have
beta-thalassemia major in the United States, and an unknown number carry the genetic trait and can pass it on to their children. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In SCD,
the mutation causes the red blood cells to form an abnormal sickle or crescent shape. The cells are fragile and deliver less oxygen to the body&#146;s tissues. They can also get stuck more easily in small blood vessels and break into pieces that can
interrupt healthy blood flow which further decrease the amount of oxygen flowing to body tissues. Almost all patients with SCD experience these painful vaso-occlusive crises, which can last from hours to days and may cause irreversible organ damage.
Current standard of care is to manage and control symptoms, and to limit the number of crises. Treatments include administration of hydroxyurea, blood transfusions, iron-chelation therapy, pain medications and antibiotics. The CDC estimates that
there are 90,000 to 100,000 Americans living with SCD, which occurs in approximately one out of every 365 African-American births and one out of every 16,300 Hispanic-American births. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">ST-400</FONT> &#151; Beta-thalassemia; <FONT STYLE="white-space:nowrap">BIVV-003</FONT> &#151; SCD
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <FONT STYLE="white-space:nowrap">ST-400</FONT> for the treatment of beta-thalassemia and our collaboration partner,
Bioverativ, is developing <FONT STYLE="white-space:nowrap">BIVV-003</FONT> for the treatment of SCD. Both <FONT STYLE="white-space:nowrap">ST-400</FONT> and <FONT STYLE="white-space:nowrap">BIVV-003</FONT> are genome-edited cell therapies that use
our ZFN genome editing technology to modify a patient&#146;s own, or autologous, hematopoietic stem/progenitor cells, or HSPCs, to produce functional red blood cells using fetal hemoglobin. Our genome editing technology can be used in HSPCs to
precisely disrupt regulatory sequences that control the expression of key transcriptional regulators, such as the BCL11A erythroid enhancer sequence, to reverse the switch from expression of the mutant adult beta-globin back to the production of
functional fetal gamma-globin. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current standard of care for beta-thalassemia includes chronic blood transfusions, while the standard
of care for SCD is a bone marrow transplant, or BMT, of HSPCs from a &#147;matched&#148; related donor, or an allogeneic </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
BMT. However, these therapies are limited due to the risk of iron overload with blood transfusions, requiring subsequent iron chelation therapy, and the scarcity of matched donors and the
significant risk of Graft versus Host Disease, or GvHD, with BMTs after transplantation of the foreign cells. By performing genome editing in HSPCs that are isolated from and subsequently returned to the same patient (i.e., an autologous HSPC
transplant), our approach has the potential to address these limitations. The goal of this approach is to develop a <FONT STYLE="white-space:nowrap">one-time</FONT> long-lasting treatment for beta-thalassemia and SCD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preclinical data from clinical-scale in vitro studies have demonstrated that <FONT STYLE="white-space:nowrap">ST-400</FONT> and <FONT
STYLE="white-space:nowrap">BIVV-003</FONT> can be manufactured by reproducible, high-level, <FONT STYLE="white-space:nowrap">ZFN-mediated</FONT> modification in HSPCs mobilized in peripheral blood at clinical production scale (&gt;108 cells), with
an <FONT STYLE="white-space:nowrap">on-target</FONT> modification efficiency of greater than 80%. Furthermore, erythroid differentiation of enhancer targeted cells showed modification of both BCL11A erythroid enhancer alleles in more than 50% of the
erythroid colonies and resulted in a greater than four-fold increase in gamma globin mRNA and protein production, compared to controls. Specificity studies of <FONT STYLE="white-space:nowrap">ST-400</FONT> and
<FONT STYLE="white-space:nowrap">BIVV-003</FONT> revealed no detectable <FONT STYLE="white-space:nowrap">off-target</FONT> activity using <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the</FONT></FONT> art, unbiased,
highly sensitive oligo-capture assays. Preclinical data from <I>in vivo</I> studies in immune-deficient mice demonstrated robust long-term (19 weeks) engraftment and that targeted gene modification was maintained through multi-lineage
differentiation in the bone marrow and peripheral blood. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our IND for <FONT STYLE="white-space:nowrap">ST-400</FONT> was cleared by the
FDA in September 2017, and we have designed an open-label, single arm Phase 1/2 clinical trial to evaluate the safety and efficacy of <FONT STYLE="white-space:nowrap">ST-400</FONT> in up to six adult subjects with beta-thalassemia. In March 2018, we
initiated the first clinical site for this beta-thalassemia study and we expect to begin enrolling patients in the first half of 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Bioverativ is our partner for <FONT STYLE="white-space:nowrap">ST-400</FONT> and is responsible for the clinical development of <FONT
STYLE="white-space:nowrap">BIVV-003</FONT> for SCD. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">CNS-Tauopathies</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are using our <FONT STYLE="white-space:nowrap">ZFP-TF</FONT> gene regulation platform to develop potential gene therapies for tauopathy
disorders, including Alzheimer&#146;s disease and other neurodegenerative diseases. We believe a reduction in tau protein levels can help reduce intracellular tau protein aggregation and the formation of neurofibrillary tangles in neurons,
potentially ameliorating or reversing disease progression.&nbsp;We believe this approach may have a significant advantage compared to monoclonal antibody-based approaches to Alzheimer&#146;s disease and other tauopathy disorders because it is
designed to selectively down-regulate the <I>tau </I>gene in neurons with the goal of reducing all forms of the tau protein globally across the CNS. In contrast, monoclonal antibody-based approaches are limited in that they can only bind to certain
forms of tau proteins. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preclinical studies in wildtype mice demonstrated that a single administration of <I>tau-</I>targeting <FONT
STYLE="white-space:nowrap">ZFP-TFs</FONT> resulted in up to 70% reduction of tau mRNA and protein expression across the entire CNS, as well as sustained and well-tolerated <FONT STYLE="white-space:nowrap">ZFP-TF</FONT> expression with minimal impact
on inflammatory markers. Additional preclinical studies in amyloid mouse models of Alzheimer&#146;s disease demonstrated up to 80% reduction of tau protein levels in the brain and cerebrospinal fluid, as well as significantly reduced neuritic
dystrophy after a single administration of <FONT STYLE="white-space:nowrap">ZFP-TFs</FONT> in mice with established disease pathology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
are currently conducting preclinical studies in NHPs to evaluate our <FONT STYLE="white-space:nowrap">ZFP-TFs</FONT> in larger mammalian species. We intend to seek a partner with disease area expertise for the clinical development and
commercialization of this program. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>C9ORF72&#150;linked ALS/FTLD </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2017, we entered into a research collaboration and license agreement with Pfizer to develop and commercialize gene therapy products
that use our ZFP TFs to treat ALS and FTLD linked to mutations of the </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
C9ORF72 gene. ALS and FTLD are part of a spectrum of neurodegenerative disorders caused by mutations in the C9ORF72 gene that involve hundreds of additional repetitions of a six base pair
sequence of DNA. This ultimately leads to the deterioration of motor neurons, in the case of ALS, or neurons in the frontal and temporal lobes, in the case of FTLD. Currently, there are no cures to halt or reverse the progression of ALS or FTLD. The
C9ORF72 mutation is linked to approximately <FONT STYLE="white-space:nowrap">one-third</FONT> of cases of familial ALS. We and Pfizer plan to investigate allele-specific <FONT STYLE="white-space:nowrap">ZFP-TFs</FONT> with the potential to
differentiate the mutant C9ORF72 allele from the wildtype allele and to specifically down-regulate expression of the mutant form of the gene. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Huntington&#146;s Disease </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Huntington&#146;s disease is an inherited, progressive neurologic disease for which there is no treatment or cure. The disease is caused by a
particular type of mutation in a single gene, the HTT gene. Most patients inherit one normal and one defective or mutant copy of the HTT gene, which causes Huntington&#146;s disease. The mutation is characterized by expansion of a repeated stretch
of DNA sequence within the gene called a &#147;CAG repeat.&#148; A normal copy of the HTT gene usually has 10 to 29 of these CAG repeats but a defective copy has many more &#151; generally greater than 39 repeats. While the protein produced by the
normal copy of the gene appears to be essential for development (mice lacking the gene do not survive to birth), the product of the mutated gene is damaging to cells. Symptoms, which include deterioration of muscle control, cognition and memory,
usually develop between 35 and 44 years of age. It is known that the greater the number of CAG repeats, the earlier the onset. Huntington&#146;s disease is usually fatal within 15 to 20 years after the onset of symptoms. The disease has a high
prevalence for an inherited disorder. According to the Huntington&#146;s Disease Society of America, approximately 30,000 people in the United States have Huntington&#146;s disease. In addition, it is estimated that approximately 200,000 people in
the United States are at risk of developing the disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research in animal models of the disease has shown that lowering the levels of
the mutant HTT protein can prevent, or even reverse, disease progression. However, to date most <FONT STYLE="white-space:nowrap">&#147;HTT-lowering&#148;</FONT> methods decrease levels of both the normal and mutant forms of HTT, raising potential
safety concerns given the importance of normal HTT protein. In collaboration with Shire, we are developing ZFP TFs that can selectively repress the expression of the mutant disease-causing form of HTT while leaving expression levels of the normal
gene unchanged. Preclinical studies in animal models of the disease are ongoing and Shire is responsible for all clinical development activities including filing the IND application. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We previously announced a data security incident involving the compromise of a senior executive&#146;s company email account. While we are
continuing to analyze the effects of the incident, along with the appropriate remediation of our information technology systems, at this time we do not believe that our ongoing clinical trials or any data from these trials have been compromised,
particularly because we restrict the receipt of data from our clinical trials to a very limited number of employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>New ZFN Architectures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2017, our scientists reported on platform advancements that substantially enhanced the precision, efficiency and specificity of ZFNs for
therapeutic genome editing. We believe these advances enable rapid development of ZFNs to target chosen genomic sites with high levels of targeted modification and with no detectable <FONT STYLE="white-space:nowrap">off-target</FONT> activity. These
advances include the development of new linkers that enable base skipping between adjacent zinc finger modules as well as a reconfiguring of the ZFN architecture to allow optional placement of the Fok1 nuclease domain at either the carboxy terminal
or the amino terminal end. The enhancements also include the identification of key amino acid substitutions that can be used to tune biochemical properties and remove <FONT STYLE="white-space:nowrap">non-specific</FONT> binding contacts between the
ZFN and the DNA backbone. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Advancements in T Cell Editing Capabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2018, we presented preclinical data demonstrating our ability to accomplish highly efficient multiplex genome editing of T cells. Efficient
multiplex editing, the ability to make multiple genetic changes in a single step, enables simultaneous disruption of certain genes to prevent the body from rejecting the treatment and integration of new genes to equip the modified T cells with
targeted antitumor functions. In the presented data, we described a T cell with four edits achieved in a single step. The four simultaneous edits included triple knockout of TCR (93% efficiency), b2 microglobulin, or B2M, (96% efficiency), CISH, a
checkpoint gene (93% efficiency), and targeted insertion of green fluorescent protein, or GFP, (91% efficiency), resulting in 76% of the modified T cells with all four edits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our T cell engineering capabilities have advanced rapidly in the last two years with improvements in our ZFN design capabilities. These novel
architectural enhancements have resulted in a <FONT STYLE="white-space:nowrap">300-fold</FONT> increase in potential design options for a given genetic sequence, yielding higher <FONT STYLE="white-space:nowrap">on-target</FONT> modification activity
in preclinical testing, with <I>ex vivo</I> editing efficiencies now reaching as high as 99.5%, and <FONT STYLE="white-space:nowrap">off-target</FONT> cleavage consistently below the level of detection. We believe these improvements potentially
allow for the use of substantially reduced doses of mRNA and AAV, enabling a highly efficient gene editing process that maintains T cell phenotypes, functions and proliferative capacity during <I>ex vivo</I> cell expansion. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Preliminary Financial Results </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
of March&nbsp;31, 2018, we had approximately $234.9&nbsp;million of cash, cash equivalents and investments. This amount is unaudited and preliminary, is subject to completion of financial closing procedures that could result in changes to the
amount, and does not present all information necessary for an understanding of our financial condition as of March&nbsp;31, 2018. This amount also does not reflect $150.0&nbsp;million that we received in April 2018 under the terms of our
collaboration agreement with Kite. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated in June 1995 in the state of Delaware and in January 2017, we changed our name from &#147;Sangamo BioSciences, Inc.&#148;
to &#147;Sangamo Therapeutics, Inc.&#148; Our principal executive offices are located at 501 Canal Boulevard, Richmond, California 94804. Our telephone number is (510) <FONT STYLE="white-space:nowrap">970-6000.</FONT> Our website is
<I>www.sangamo.com</I>. Information found on, or accessible through, our website is not a part of, and is not incorporated into, this prospectus supplement or the accompanying prospectus, and you should not consider it part of this prospectus
supplement or the accompanying prospectus. Our website address is included in this document as an inactive textual reference only. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Offering </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock offered by us </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding immediately after this offering </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Option to purchase additional shares </P></TD>
<TD>The underwriters have an option to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of our common stock, solely to cover overallotments. The underwriters may exercise this option at any
time within 30&nbsp;days from the date of this prospectus supplement. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We intend to use the net proceeds from this offering for working capital and other general corporate purposes, including support for our own and our partnered gene therapy, genome editing, cell therapy and gene regulation product candidates and
research programs, our manufacturing facilities and other business development activities. See &#147;Use of Proceeds.&#148; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Global Select Market Symbol </P></TD>
<TD>SGMO </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>Investing in our common stock involves a high degree of risk. See &#147;Risk Factors.&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our
common stock to be outstanding immediately after this offering as shown above is based on 85,598,534 shares of common stock outstanding as of December&nbsp;31, 2017 and excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">8,287,456 shares of our common stock issuable upon the exercise of options outstanding as of December&nbsp;31, 2017, having a weighted-average exercise price of $7.77 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">80,172 shares of our common stock issuable upon the vesting of restricted stock units outstanding as of December&nbsp;31, 2017; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">3,601,633 shares of our common stock reserved for future issuance under our Amended and Restated 2013 Stock Incentive Plan, or the 2013 Plan, as of December&nbsp;31, 2017; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">835,674 additional shares of our common stock reserved for future issuance under our 2010 Employee Stock Purchase Plan, or the ESPP, as of December&nbsp;31, 2017. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the number of shares of our common stock to be outstanding immediately after this offering as shown above excludes the up to
$75.0&nbsp;million of our common stock that remained available for sale at December&nbsp;31, 2017 pursuant to an Amended and Restated <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">At-the-Market</FONT></FONT> Offering Program
Sales Agreement, or the ATM Agreement, that we entered into with Cowen and Company, LLC, or Cowen, on May&nbsp;26, 2017. Moreover, our compensation committee has reserved an additional 2,500,000 shares of our common stock for issuance under the
ESPP, subject to the receipt of stockholder approval at our 2018 annual meeting of stockholders anticipated to be held on June&nbsp;11, 2018, or the 2018 annual meeting. At the 2018 annual meeting, we will also be asking our stockholders to approve
our 2018 Equity Incentive Plan, or the 2018 Plan, which is intended to be the successor of the 2013 Plan, and which will include a new reserve of 8,800,000 shares of our common stock (in addition to the shares of our common stock that are, or would
become, available under our 2013 Plan). The number of shares of our common stock to be outstanding immediately after this offering as shown above does not reflect these additional shares. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise indicated, all information in this prospectus supplement assumes no
exercise by the underwriters of their option to purchase additional shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gilead Sciences, Inc. has indicated an interest in purchasing
up to approximately $50&nbsp;million of the shares of common stock offered hereby at the price offered to the public. Because this indication of interest is not a binding agreement or commitment to purchase, this entity may elect not to purchase any
shares in this offering, or the underwriters may elect not to sell any shares in this offering to it. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom570679_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. Before deciding whether to invest in our common stock, you should consider
carefully the risks described below and discussed under the section captioned &#147;Risk Factors&#148; contained in our Current Report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> filed with the SEC on April&nbsp;17, 2018 and in our
other filings that are incorporated by reference in this prospectus supplement and the accompanying prospectus in its entirety, together with the other information in this prospectus supplement, the accompanying prospectus, and the documents
incorporated by reference, and in any free writing prospectus that we have authorized for use in connection with this offering. If any of these risks actually occur, our business, financial condition, results of operations or prospects could be
seriously harmed. This could cause the trading price of our common stock to decline, resulting in a loss of all or part of your investment. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks
Relating to this Offering and our Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our stock price has been volatile and may continue to be volatile, which could result in
substantial losses for investors in this offering. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our stock price has been volatile and may continue to be volatile, which could
cause investors in this offering to incur substantial losses. An active public market for our common stock may not be sustained, and the market price of our common stock may continue to be highly volatile. The market price of our common stock has
fluctuated significantly and may continue to be subject to substantial volatility in response to various factors, some of which are beyond our control, including but not limited to the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements by us or collaborators providing updates on the progress or development status of product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">data from clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">initiation or termination of clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in market valuations of similar companies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">overall market and economic conditions, including the equity markets for emerging biotechnology companies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">deviations in our results of operations from the guidance given by us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements by us or our competitors of new or enhanced products, technologies or services or significant contracts, acquisitions, strategic relationships, joint ventures or capital commitments; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcement of changes in business and operations by our collaborators and partners, or changes in our existing collaboration agreements; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory developments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes, by one or more of our security analysts, in recommendations, ratings or coverage of our stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions or departures of key personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">future sales of our common stock or other securities by us, management or directors, liquidation of institutional funds that comprised large holdings of our stock; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">decreases in our cash balances. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Actual or potential sales of our common stock by our
employees, including our executive officers, pursuant to <FONT STYLE="white-space:nowrap">pre-arranged</FONT> stock trading plans could cause our stock price to fall or prevent it from increasing for numerous reasons, and actual or potential sales
by such persons could be viewed negatively by other investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the guidelines specified under Rule <FONT
STYLE="white-space:nowrap">10b5-1</FONT> of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and our policies regarding stock transactions, a number of our employees, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including executive officers and members of our board of directors, have adopted and may continue to adopt stock trading plans pursuant to which they have arranged to sell shares of our common
stock from time to time in the future. Generally, sales under such plans by our executive officers and directors require public filings. Actual or potential sales of our common stock by such persons could cause the price of our common stock to fall
or prevent it from increasing for numerous reasons. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you purchase shares of common stock in this offering, you will experience immediate and
substantial dilution in your investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because the price per share of our common stock being offered is substantially higher
than the net tangible book value per share of our common stock, you will suffer immediate and substantial dilution with respect to the net tangible book value of the common stock you purchase in this offering. Based on the public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share and our net tangible book value as of December&nbsp;31, 2017, if you purchase shares of common stock in this offering, you would suffer
immediate and substantial dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share with respect to the net tangible book value of the common stock. See the section entitled
&#147;Dilution&#148; for a more detailed discussion of the dilution you will incur if you purchase common stock in this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future sales and
issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders, including investors in this offering, and could
cause our stock price to fall. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional capital will be needed in the future to continue our planned operations. To the extent
we raise additional capital by issuing equity securities, including pursuant to the ATM Agreement, our stockholders, including investors in this offering, may experience substantial dilution. We may sell common stock, convertible securities or other
equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, our stockholders, including investors
who purchase shares of common stock in this offering, will experience additional dilution, and any such issuances may result in downward pressure on the price of our common stock. We also cannot assure you that we will be able to sell shares or
other securities in any other offering at a price per share that is equal to or greater than the price per share paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to
existing stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will have broad discretion in the use of the net proceeds from this offering and may not use them effectively.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will have broad discretion in the use of the net proceeds from this offering and could spend the proceeds in ways that do not
improve our results of operations or enhance the value of our common stock. Our failure to apply these funds effectively could have a material adverse effect on our business, impair or delay our ability to develop our product candidates, and cause
the price of our common stock to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our stock price is also influenced by public perception of gene therapy and government regulation of
potential products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reports of serious adverse events in a retroviral gene transfer trial for infants with <FONT
STYLE="white-space:nowrap">X-linked</FONT> severe combined immunodeficiency <FONT STYLE="white-space:nowrap">(X-linked</FONT> SCID) in France and subsequent FDA actions putting related trials on hold in the United States had a significant negative
impact on the public perception and stock price of certain companies involved in gene therapy. Stock prices of these companies declined whether or not the specific company was involved with retroviral gene transfer for the treatment of infants with <FONT
STYLE="white-space:nowrap">X-linked</FONT> SCID, or whether the specific company&#146;s clinical trials were placed on hold in connection with these events. Other potential adverse events in the field of gene therapy may occur in the future that
could result in greater governmental regulation of our potential products and potential regulatory delays relating to the testing or approval of our potential products. These external events may have a negative impact on public perception of our
business, which could cause our stock price to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do not publish research or publish inaccurate or unfavorable
research about our business, our stock price and trading volume could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our common stock will depend
in part on the research and reports that securities or industry analysts publish about us or our business. In the event securities or industry analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our
business, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to
decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain future earnings for the
development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders, including investors in this offering, will therefore be limited to the
appreciation of their stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-takeover provisions in our certificate of incorporation and Delaware law could make an acquisition of our company
more difficult and could prevent attempts by our stockholders, including investors in this offering, to remove or replace current management. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Anti-takeover provisions of Delaware law and in our certificate of incorporation and our bylaws may discourage, delay or prevent a change in
control of our company, even if a change in control would be beneficial to our stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders, including investors in this offering, to replace or remove our
current management by making it more difficult for stockholders to replace members of our board of directors. In particular, under our certificate of incorporation our board of directors may issue up to 5,000,000 shares of preferred stock with
rights and privileges that might be senior to our common stock, without the consent of the holders of the common stock. Moreover, without any further vote or action on the part of the stockholders, the board of directors would have the authority to
determine the price, rights, preferences, privileges, and restrictions of the preferred stock. This preferred stock, if it is ever issued, may have preference over, and harm the rights of, the holders of common stock. Although the issuance of this
preferred stock would provide us with flexibility in connection with possible acquisitions and other corporate purposes, this issuance may make it more difficult for a third party to acquire a majority of our outstanding voting stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similarly, our authorized but unissued common stock is available for future issuance without stockholder approval. Our certificate of
incorporation further provides that stockholders may not take action by written consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our amended and restated bylaws, as
amended: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish advance notice requirements for nominations for election to the board of directors or proposing matters that can be acted upon at stockholders&#146; meetings; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prohibit stockholders from calling a special meeting of stockholders. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also subject to
Section&nbsp;203 of the Delaware General Corporation Law, which provides, subject to certain exceptions, that if a person acquires 15% of our voting stock, the person is an &#147;interested stockholder&#148; and may not engage in &#147;business
combinations&#148; with us for a period of three years from the time the person acquired 15% or more or our voting stock. The application of Section&nbsp;203 may, in some circumstances, deter or prevent a change in control of our company even when
such change may be beneficial to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our amended and restated bylaws, as amended, provide that the Court of Chancery of the State of
Delaware will be the exclusive forum for the adjudication of certain disputes, which could limit the ability of investors in this offering to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated bylaws, as amended, provide that the Court of Chancery of the State of Delaware is the sole and exclusive
forum for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any derivative action or proceeding brought on our behalf; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of Sangamo to us or our stockholders; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any action asserting a claim arising pursuant to any provision of the General Corporation Law of the State of Delaware; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any action asserting a claim governed by the internal affairs doctrine. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This provision
further provides that any person or entity that acquires any interest in shares of our capital stock, including investors in this offering, will be deemed to have notice of and consented to the provisions of such provision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This provision may limit the ability of investors in this offering to bring a claim in a judicial forum that it finds favorable for disputes
with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers, and other employees. If a court were to find this provision to be inapplicable or unenforceable in an action, we may incur
additional costs associated with resolving the dispute in other jurisdictions, which could seriously harm our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom570679_4"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement, the accompanying prospectus, the documents incorporated by reference and any free writing prospectus that we have
authorized for use in connection with this offering contain &#147;forward-looking statements&#148; within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of the Exchange Act.
These statements relate to future events or to our future operating or financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially
different from any future results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements may include, but are not limited to, statements about: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our strategy; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">anticipated product candidate development and potential commercialization of any resulting products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the initiation, scope, rate of progress, enrollment, anticipated results and timing of our preclinical studies and clinical trials and those of our collaborators or strategic partners; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the therapeutic and commercial potential of, and the ability of Sangamo and our collaborators or strategic partners to advance the development of, product candidates using our ZFP technology platform, including our
ability to effectively deliver our ZFNs and ZFP TFs to produce a beneficial therapeutic effect; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to establish and maintain collaborative, licensing and other similar arrangements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">anticipated revenues from existing and new collaborations and the timing thereof; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our research and development and other expenses; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain adequate preclinical and clinical supplies of our product candidates from current and potential new suppliers and manufacturers; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the ability of Sangamo and our collaborators or strategic partners to obtain and maintain regulatory approvals for product candidates using our ZFP technology platform; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to comply with, and the impact of, regulatory requirements, obligations and restrictions on our business; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others, including our ability to obtain rights to the gene transfer technologies
required to develop and commercialize our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our estimates regarding the sufficiency of our cash resources and our expenses, capital requirements and need for additional financing, and our ability to obtain additional financing; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to manage the growth of our business; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our projected operating and financial performance; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our operational and legal risks; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our intended use of the net proceeds from this offering; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our plans, objectives, expectations and intentions and any other statements that are not historical facts. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some cases, you can identify forward-looking statements by terms such as &#147;anticipates,&#148; &#147;believes,&#148; &#147;could,&#148;
&#147;estimates,&#148; &#147;expects,&#148; &#147;may,&#148; &#147;plans,&#148; &#147;potential,&#148; &#147;predicts,&#148; &#147;projects,&#148; &#147;should,&#148; &#147;would,&#148; &#147;will&#148; and similar expressions intended to identify
forward-looking statements. These statements reflect our current views with respect to future events, are based on assumptions and are subject to risks and uncertainties. Given these risks and uncertainties, you should not place undue reliance on
these forward-looking statements. We </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
discuss many of these risks, uncertainties and other factors in greater detail under the heading &#147;Risk Factors&#148; of this prospectus supplement and under the section captioned &#147;Risk
Factors&#148; contained in our Current Report on <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on April&nbsp;17, 2018 and in our other filings that are incorporated by reference in this prospectus supplement and the accompanying
prospectus. Also, these forward-looking statements represent our estimates and assumptions only as of the date of the document containing the applicable statement. Unless required by law, we undertake no obligation to update or revise any
forward-looking statements to reflect new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. You
should read carefully this prospectus supplement and the accompanying prospectus, the documents incorporated herein by reference as described under the heading &#147;Incorporation of Certain Information by Reference&#148; in this prospectus
supplement, and any free writing prospectus that we have authorized for use in connection with this offering completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the
forward-looking statements in the foregoing documents by these cautionary statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom570679_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds we will receive from the sale of the $200,000,000 of shares of our common stock that we are offering will be
approximately $187.7 million (or approximately $215.9 million if the underwriters exercise in full their over-allotment option to purchase up to an additional $30,000,000 of shares of our common stock), after deducting the estimated underwriting
discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assuming we issue 11,019,284 shares in this offering, a $1.00
increase (decrease) in the assumed public offering price of $18.15 per share would increase (decrease) the net proceeds to us from this offering by approximately $10.4 million, assuming that the number of shares offered by us, as set forth above,
remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, a one million share increase (decrease) in the number of shares offered by us, as set forth above,
would increase (decrease) the net proceeds to us by $17.1 million, assuming the assumed public offering price of $18.15 per share remains the same, and after deducting the estimated underwriting discounts and commissions and estimated offering
expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from this offering for working capital and other general corporate purposes,
including support for our own and our partnered gene therapy, genome editing, cell therapy and gene regulation product candidates and research programs, our manufacturing facilities and other business development activities. In addition, we may use
a portion of the net proceeds to acquire drugs or drug candidates, technologies, businesses or other assets, although we have no current plans, commitments or agreements to do so as of the date of this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amounts and timing of the expenditures may vary significantly, depending upon numerous factors, including our proprietary research and
therapeutic programs and our clinical trials as well as the amount of cash used in our operations<I>.</I>&nbsp;Accordingly, our management will have broad discretion in the application of the net proceeds and investors will be relying upon the
judgment of our management regarding the application of these proceeds<I>.</I>&nbsp;We reserve the right to change the use of these proceeds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pending these uses, we intend to invest the proceeds of this offering in short-term, investment grade interest-bearing securities. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom570679_6"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not paid dividends on our common stock, and currently do not plan to pay any cash dividends in the foreseeable future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom570679_7"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our net tangible book value as of December&nbsp;31, 2017 was $186.3 million, or approximately $2.18 per share. Net tangible book value is
total assets minus the sum of liabilities and intangible assets. Net tangible book value per share is net tangible book value divided by the total number of shares of common stock outstanding as of December&nbsp;31, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dilution in net tangible book value per share represents the difference between the amount per share paid by purchasers of shares of common
stock in this public offering and the net tangible book value per share of our common stock immediately after completion of this public offering. After giving effect to the sale
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in this offering at the public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, our as adjusted net tangible
book value as of December&nbsp;31, 2017 would have been approximately $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. This represents an immediate increase in net tangible book value of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to existing stockholders and immediate dilution in net tangible book value of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to investors purchasing our common stock in this offering at the public offering price. The following table illustrates this dilution on a
per share basis: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book value per share as of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in net tangible book value per share attributable to this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book value per share as of December&nbsp;31, 2017 after giving effect to
this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to investors purchasing our common stock in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the underwriters exercise in full their option to purchase
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of common stock at the public offering price of $
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the as adjusted net tangible book value after this offering would be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, representing an increase in net tangible book value of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to existing stockholders and immediate dilution in net tangible book value of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to investors purchasing our common stock in this offering at the public offering price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above discussion and table are based on 85,598,534 shares of common stock issued and outstanding as of December&nbsp;31, 2017 and exclude:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">8,287,456 shares of our common stock issuable upon the exercise of options outstanding as of December&nbsp;31, 2017, having a weighted-average exercise price of $7.77 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">80,172 shares of our common stock issuable upon the vesting of restricted stock units outstanding as of December&nbsp;31, 2017; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">3,601,633 shares of our common stock reserved for future issuance under the 2013 Plan as of December&nbsp;31, 2017; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">835,674 additional shares of our common stock reserved for future issuance under the ESPP as of December&nbsp;31, 2017. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the above discussion and table exclude the up to $75.0&nbsp;million of our common stock that remained available for sale at
December&nbsp;31, 2017 pursuant to the ATM Agreement with Cowen. Moreover, our compensation committee has reserved an additional 2,500,000 shares of our common stock for issuance under the ESPP, subject to the receipt of stockholder approval at the
2018 annual meeting. At the 2018 annual meeting, we will also be asking our stockholders to approve our 2018 Plan, which is intended to be the successor of the 2013 Plan, and which will include a new reserve of 8,800,000 shares of our common stock
(in addition to the shares of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our common stock that are, or would become, available under our 2013 Plan). The above discussion and table do not reflect these additional shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that outstanding options are exercised or restricted stock unit awards vest, you will experience further dilution. In addition,
we may choose to raise additional capital due to market conditions or strategic considerations, including pursuant to the ATM Agreement, even if we believe we have sufficient funds for our current or future operating plans. To the extent that
additional capital is raised through the sale of our common stock, or securities convertible into or exchangeable or exercisable for common stock, the issuance of these securities could result in further dilution to investors in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom570679_8"></A>PRICE RANGE OF COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is traded on The Nasdaq Global Select Market under the symbol &#147;SGMO.&#148; The following table sets forth, for the
periods indicated, the reported high and low intraday sales prices per share of our common stock as reported on The Nasdaq Global Select Market: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fourth Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fourth Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second Quarter (though April&nbsp;23, 2018)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The last reported sale price of our common stock on The Nasdaq Global Select Market on April&nbsp;23, 2018 was
$18.15 per share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom570679_9"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES <FONT
STYLE="white-space:nowrap">FOR&nbsp;NON-U.S.&nbsp;HOLDERS</FONT> OF COMMON STOCK </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary describes the material U.S.
federal income tax consequences of the acquisition, ownership and disposition of our common stock acquired in this offering <FONT STYLE="white-space:nowrap">by&nbsp;Non-U.S.&nbsp;Holders</FONT> (as defined below).&nbsp;This discussion is not a
complete analysis of all potential U.S. federal income tax consequences relating thereto, and does not deal with foreign, state and local consequences that may be relevant <FONT STYLE="white-space:nowrap">to&nbsp;Non-U.S.&nbsp;Holders</FONT> in
light of their particular circumstances, nor does it address U.S. federal tax consequences (such as gift and estate taxes) other than income taxes.&nbsp;Special rules different from those described below may apply to
<FONT STYLE="white-space:nowrap">certain&nbsp;Non-U.S.&nbsp;Holders</FONT> that are subject to special treatment under the Internal Revenue Code of 1986, as amended (or the Code), such as financial institutions, insurance <FONT
STYLE="white-space:nowrap">companies,&nbsp;tax-exempt&nbsp;organizations,</FONT> broker-dealers and traders in securities, U.S. expatriates, &#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies,&#148; corporations
that accumulate earnings to avoid U.S. federal income tax, corporations organized outside of the United States, any state thereof or the District of Columbia that are nonetheless treated as United&nbsp;States income taxpayers for United States
federal tax purposes, persons that hold our common stock as part of a &#147;straddle,&#148; &#147;hedge,&#148; &#147;conversion transaction,&#148; &#147;synthetic security&#148; or integrated investment or other risk reduction strategy, persons who
acquire our common stock through the exercise of an option or otherwise as compensation, accrual-method taxpayers subject to special tax accounting rules under Section&nbsp;451(b) of the Code, persons subject to the alternative minimum tax or
federal Medicare contribution tax on net investment income, partnerships and other pass-through entities or arrangements, and investors in such pass-through entities or arrangements. <FONT STYLE="white-space:nowrap">Such&nbsp;Non-U.S.</FONT> Holders
are urged to consult their own tax advisors to determine the U.S. federal, state, local and other tax consequences that may be relevant to them.&nbsp;Furthermore, the discussion below is based upon the provisions of the Code, and U.S. Treasury
regulations, rulings and judicial decisions thereunder as of the date hereof, and such authorities may be repealed, revoked or modified, perhaps retroactively, so as to result in U.S. federal income tax consequences different from those discussed
below.&nbsp;We have not requested a ruling from the U.S. Internal Revenue Service, or IRS, with respect to the statements made and the conclusions reached in the following summary, and there can be no assurance that the IRS will agree with such
statements and conclusions.&nbsp;This discussion assumes that <FONT STYLE="white-space:nowrap">the&nbsp;Non-U.S.&nbsp;Holder</FONT> holds our common stock as a &#147;capital asset&#148; within the meaning of Section&nbsp;1221 of the Code (generally,
property held for investment). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Persons considering the purchase of our common stock pursuant to this offering should consult their own
tax advisors concerning the U.S. federal income, estate and other tax consequences of acquiring, owning and disposing of our common stock in light of their particular situations as well as any consequences arising under the laws of any other taxing
jurisdiction, including any state, local or foreign tax consequences. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this discussion,
<FONT STYLE="white-space:nowrap">a&nbsp;&#147;Non-U.S.&nbsp;Holder&#148;</FONT> is, for U.S. federal income tax purposes, a beneficial owner of common stock that is neither a U.S. Holder, nor a partnership (or other entity treated as a partnership
for U.S. federal income tax purposes regardless of its place of organization or formation).&nbsp;A &#147;U.S. Holder&#148; means a beneficial owner of our common stock that is for U.S. federal income tax purposes any of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an individual who is a citizen or resident of the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a corporation or other entity treated as a corporation for U.S. federal income tax purposes created or organized in or under the laws of the U.S., any state thereof or the District of Columbia; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an estate the income of which is subject to U.S. federal income taxation regardless of its source; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a trust if it (1)&nbsp;is subject to the primary supervision of a court within the U.S. and one or more U.S. persons have the authority to control all substantial decisions of the trust or (2)&nbsp;has a valid election
in effect under applicable U.S. Treasury regulations to be treated as a U.S. person. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Distributions, if any, made on our common stock to <FONT STYLE="white-space:nowrap">a&nbsp;Non-U.S.&nbsp;Holder</FONT> to the extent made out
of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles) generally will constitute dividends for U.S. tax purposes and will be subject to withholding tax at a 30% rate or such lower rate as may be
specified by an applicable income tax treaty, subject to the discussion below regarding foreign accounts.&nbsp;To obtain a reduced rate of withholding under a treaty, <FONT STYLE="white-space:nowrap">a&nbsp;Non-U.S.&nbsp;Holder</FONT> generally will
be required to provide us with a properly executed <FONT STYLE="white-space:nowrap">IRS&nbsp;Form&nbsp;W-8BEN&nbsp;(in</FONT> the case of individuals) or IRS
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN-E&nbsp;(in</FONT></FONT> the case of entities), or other appropriate form, including a U.S. taxpayer identification number, or in certain circumstances, a foreign tax
identifying number, and certifying <FONT STYLE="white-space:nowrap">the&nbsp;Non-U.S.&nbsp;Holder&#146;s</FONT> entitlement to benefits under that treaty. This certification must be provided to us or our paying agent prior to the payment of
dividends and must be updated periodically. In the case of <FONT STYLE="white-space:nowrap">a&nbsp;Non-U.S.&nbsp;Holder</FONT> that is an entity, U.S. Treasury regulations and the relevant tax treaty provide rules to determine whether, for purposes
of determining the applicability of a tax treaty, dividends will be treated as paid to the entity or to those holding an interest in that entity.&nbsp;If <FONT STYLE="white-space:nowrap">a&nbsp;Non-U.S.&nbsp;Holder</FONT> holds stock through a
financial institution or other agent acting on the holder&#146;s behalf, the holder will be required to provide appropriate documentation to such agent.&nbsp;The holder&#146;s agent will then be required to provide certification to us or our paying
agent, either directly or through other intermediaries.&nbsp;If you are eligible for a reduced rate of U.S. federal withholding tax under an income tax treaty and you do not timely file the required certification, you may be able to obtain a refund
or credit of any excess amounts withheld by timely filing an appropriate claim for a refund with the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We generally are not required
to withhold tax on dividends paid to <FONT STYLE="white-space:nowrap">a&nbsp;Non-U.S.&nbsp;Holder</FONT> that are effectively connected with <FONT STYLE="white-space:nowrap">the&nbsp;Non-U.S.&nbsp;Holder&#146;s</FONT> conduct of a trade or business
within the United States (and, if required by an applicable income tax treaty, are attributable to a permanent establishment that such holder maintains in the United States) if a properly executed
<FONT STYLE="white-space:nowrap">IRS&nbsp;Form&nbsp;W-8ECI,&nbsp;stating</FONT> that the dividends are so connected, is furnished to us (or, if stock is held through a financial institution or other agent, to such agent).&nbsp;In general, such
effectively connected dividends will be subject to U.S. federal income tax, on a net income basis at the regular graduated rates applicable to U.S. residents.&nbsp;A <FONT STYLE="white-space:nowrap">corporate&nbsp;Non-U.S.&nbsp;Holder</FONT>
receiving effectively connected dividends may also be subject to an additional &#147;branch profits tax,&#148; which is imposed, under certain circumstances, at a rate of 30% (or such lower rate as may be specified by an applicable treaty) on the <FONT
STYLE="white-space:nowrap">corporate&nbsp;Non-U.S.&nbsp;Holder&#146;s</FONT> effectively connected earnings and profits, subject to certain <FONT STYLE="white-space:nowrap">adjustments.&nbsp;Non-U.S.&nbsp;Holders</FONT> should consult their tax
advisors regarding any applicable income tax treaties that may provide for different rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent distributions on our common
stock, if any, exceed our current and accumulated earnings and profits, they will first reduce <FONT STYLE="white-space:nowrap">the&nbsp;Non-U.S.Holder&#146;s</FONT> adjusted basis in our common stock, but not below zero, and then will be treated as
gain to the extent of any excess, and taxed in the same manner as gain realized from a sale or other disposition of common stock as described in the next section. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gain on Disposition of Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussion below regarding backup withholding and foreign accounts,
<FONT STYLE="white-space:nowrap">a&nbsp;Non-U.S.&nbsp;Holder</FONT> generally will not be subject to U.S. federal income tax with respect to gain realized on a sale or other disposition of our common stock unless (a)&nbsp;the gain is effectively
connected with a trade or business of such holder in the United States (and, if required by an applicable income tax treaty, is attributable to a permanent establishment that such holder maintains in the United States), <FONT
STYLE="white-space:nowrap">(b)&nbsp;the&nbsp;Non-U.S.&nbsp;Holder</FONT> is a nonresident alien individual and is present in the United States for 183 or more days in the taxable year of the disposition and certain other conditions are met or
(c)&nbsp;we are or have been a &#147;United States real property holding corporation&#148; within the meaning of Code Section&nbsp;897(c)(2) at any time within the shorter of the five-year period preceding such disposition or such holder&#146;s
holding period.&nbsp;In general, we would be a U.S. real property holding corporation if interests in U.S. real estate comprise (by fair market value) at least half of our business assets.&nbsp;We believe that we have not been and we are not, and do
not anticipate becoming, a U.S. real property holding corporation.&nbsp;Even if we are treated as a U.S. real property holding corporation, gain realized by <FONT STYLE="white-space:nowrap">a&nbsp;Non-U.S.&nbsp;Holder</FONT> on a disposition
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of our common stock will not be subject to U.S. federal income tax so long as <FONT STYLE="white-space:nowrap">(1)&nbsp;the&nbsp;Non-U.S.&nbsp;Holder</FONT> owned, directly, indirectly and
constructively, no more than five percent of our common stock at all times within the shorter of (i)&nbsp;the five-year period preceding the disposition or (ii)&nbsp;the holder&#146;s holding period and (2)&nbsp;our common stock is regularly traded
on an established securities market. There can be no assurance that our common stock will continue to qualify as regularly traded on an established securities market. If any gain on your disposition is taxable because we are a United States real
property holding corporation and your ownership of our common stock exceeds 5%, you will be taxed on such disposition generally in the manner applicable to U.S. persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are <FONT STYLE="white-space:nowrap">a&nbsp;Non-U.S.&nbsp;Holder</FONT> described in (a)&nbsp;above, you will be required to pay tax on
the net gain derived from the sale at regular graduated U.S. federal income tax rates, and <FONT STYLE="white-space:nowrap">corporate&nbsp;Non-U.S.&nbsp;Holders</FONT> described in (a)&nbsp;above may be subject to the additional branch profits tax
at a 30% rate or such lower rate as may be specified by an applicable income tax treaty.&nbsp;Gain described in (b)&nbsp;above will be subject to U.S. federal income tax at a flat 30% rate or such lower rate as may be specified by an applicable
income tax treaty, which gain may be offset by certain U.S.-source capital losses (even though you are not considered a resident of the U.S.), provided that <FONT STYLE="white-space:nowrap">the&nbsp;Non-U.S.&nbsp;Holder</FONT> has timely filed U.S.
federal income tax returns with respect to such losses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Reporting Requirements and Backup Withholding </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, we must report information to the IRS with respect to any dividends we pay on our common stock (even if the payments are exempt from
withholding), including the amount of any such dividends, the name and address of the recipient, and the amount, if any, of tax withheld.&nbsp;A similar report is sent to the holder to whom any such dividends are paid.&nbsp;Pursuant to tax treaties
or certain other agreements, the IRS may make its reports available to tax authorities in the recipient&#146;s country of residence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends paid by us (or our paying agents) to <FONT STYLE="white-space:nowrap">a&nbsp;Non-U.S.&nbsp;Holder</FONT> may also be subject to U.S.
backup withholding.&nbsp;U.S. backup withholding generally will not apply to <FONT STYLE="white-space:nowrap">a&nbsp;Non-U.S.&nbsp;Holder</FONT> who provides a properly executed
<FONT STYLE="white-space:nowrap">IRS&nbsp;Form&nbsp;W-8BEN,&nbsp;IRS</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN-E,&nbsp;or</FONT></FONT> IRS
<FONT STYLE="white-space:nowrap">Form&nbsp;W-ECI,&nbsp;or</FONT> otherwise establishes an exemption. Notwithstanding the foregoing, backup withholding may apply if the payor has actual knowledge, or reason to know, that the holder is a U.S. person
who is not an exempt recipient. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">U.S. information reporting and backup withholding requirements generally will apply to the proceeds of a
disposition of our common stock effected by or through a U.S. office of any broker, U.S. or foreign, except that information reporting and such requirements may be avoided if the holder provides a properly executed
<FONT STYLE="white-space:nowrap">IRS&nbsp;Form&nbsp;W-8BEN&nbsp;or</FONT> IRS <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN-E&nbsp;or</FONT></FONT> otherwise meets documentary evidence requirements for <FONT
STYLE="white-space:nowrap">establishing&nbsp;non-U.S.person</FONT> status or otherwise establishes an exemption.&nbsp;Generally, U.S. information reporting and backup withholding requirements will not apply to a payment of disposition proceeds to <FONT
STYLE="white-space:nowrap">a&nbsp;Non-U.S.&nbsp;Holder</FONT> where the transaction is effected outside the U.S. through <FONT STYLE="white-space:nowrap">a&nbsp;non-U.S.&nbsp;office</FONT> of
<FONT STYLE="white-space:nowrap">a&nbsp;non-U.S.broker.&nbsp;Information</FONT> reporting and backup withholding requirements may, however, apply to a payment of disposition proceeds if the broker has actual knowledge, or reason to know, that the
holder is, in fact, a U.S. person.&nbsp;For information reporting purposes, certain brokers with substantial U.S. ownership or operations will generally be treated in a manner similar to U.S. brokers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be credited against the tax liability
of persons subject to backup withholding, provided that the required information is timely furnished to the IRS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Foreign Accounts </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sections 1471 through 1474 of the Code (commonly referred to as FATCA) impose a U.S. federal withholding tax of 30% on certain payments,
including dividends paid on and the gross proceeds of a disposition of our common stock paid to a foreign financial institution (as specifically defined by applicable rules) unless </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such institution enters into an agreement with the U.S. government to withhold on certain payments and to collect and provide to the U.S. tax authorities substantial information regarding U.S.
account holders of such institution (which includes certain equity holders of such institution, as well as certain account holders that are foreign entities with U.S. owners).&nbsp;FATCA also generally imposes a federal withholding tax of 30% on
certain payments, including dividends paid on and the gross proceeds of a disposition of our common stock to <FONT STYLE="white-space:nowrap">a&nbsp;non-financial&nbsp;foreign</FONT> entity unless such entity provides the withholding agent with
either a certification that it does not have any substantial direct or indirect U.S. owners or provides information regarding substantial direct and indirect U.S. owners of the entity.&nbsp;An intergovernmental agreement between the United States
and an applicable foreign country may modify those requirements. The withholding tax described above will not apply if the foreign financial institution <FONT STYLE="white-space:nowrap">or&nbsp;non-financial&nbsp;foreign</FONT> entity otherwise
qualifies for an exemption from the rules.&nbsp;Holders are encouraged to consult with their own tax advisors regarding the possible implications of FATCA on their investment in our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The withholding provisions described above currently apply to payments of dividends, and will apply to payments of gross proceeds from a sale
or other disposition of common stock on or after January&nbsp;1, 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS OWN TAX ADVISOR REGARDING THE TAX
CONSEQUENCES OF PURCHASING, HOLDING AND DISPOSING OF OUR COMMON STOCK, INCLUDING THE CONSEQUENCES OF ANY PROPOSED OR RECENT CHANGE IN APPLICABLE LAW. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom570679_10"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated, J.P. Morgan Securities LLC and Cowen and Company, LLC are acting as
representatives of each of the underwriters named below. Subject to the terms and conditions set forth in an underwriting agreement among us and the underwriters, we have agreed to sell to the underwriters, and each of the underwriters has agreed,
severally and not jointly, to purchase from us, the number of shares of common stock set forth opposite its name below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Underwriter</U></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B><br><B>of&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions set forth in the underwriting agreement, the underwriters have agreed,
severally and not jointly, to purchase all of the shares sold under the underwriting agreement if any of these shares are purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the nondefaulting
underwriters may be increased or the underwriting agreement may be terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the underwriters against
certain liabilities, including liabilities under the Securities Act, or to contribute to payments the underwriters may be required to make in respect of those liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters are offering the shares, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal
matters by their counsel, including the validity of the shares, and other conditions contained in the underwriting agreement, such as the receipt by the underwriters of officer&#146;s certificates and legal opinions. Sales of shares made outside of
the United States may be made by affiliates of the underwriters. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commissions and Discounts </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
representatives have advised us that the underwriters propose initially to offer the shares to the public at the public offering price set forth on the cover page of this prospectus and to dealers at that price less a concession not in excess of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. After the initial offering, the public offering price, concession or any other term of the offering may be changed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the public offering price, underwriting discount and proceeds before expenses to us. The information assumes either
no exercise or full exercise by the underwriters of their option to purchase additional shares. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without&nbsp;Option</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>With&nbsp;Option</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to Sangamo</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The expenses of the offering, not including the underwriting discount, are estimated at $295,000 and are payable by us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Option to Purchase Additional Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have granted an
option to the underwriters, exercisable for 30 days after the date of this prospectus, to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares at the public offering price, less the underwriting discount, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
solely to cover overallotments. If the underwriters exercise this option, each will be obligated, subject to conditions contained in the underwriting agreement, to purchase a number of additional
shares proportionate to that underwriter&#146;s initial amount reflected in the above table. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Sales of Similar Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed not to sell or transfer any common stock or securities convertible into, exchangeable for, exercisable for, or repayable with
common stock, for 90 days after the date of this prospectus without first obtaining the written consent of the Representatives. Our executive officers and directors have agreed not to sell or transfer any common stock or securities convertible into,
exchangeable for, exercisable for, or repayable with common stock, for 45 days after the date of this prospectus without first obtaining the written consent of the Representatives. Specifically, we and these other persons have agreed, with certain
limited exceptions, not to directly or indirectly: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">offer, pledge, sell or contract to sell any common stock, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sell any option or contract to purchase any common stock, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">purchase any option or contract to sell any common stock, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">grant any option, right or warrant for the sale of any common stock, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">lend or otherwise dispose of or transfer any common stock, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">request or demand that we file a registration statement related to the common stock, or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">enter into any swap or other agreement that transfers, in whole or in part, the economic consequence of ownership of any common stock whether any such swap or transaction is to be settled by delivery of shares or other
securities, in cash or otherwise. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <FONT STYLE="white-space:nowrap">lock-up</FONT> provision applies to common stock
and to securities convertible into or exchangeable or exercisable for or repayable with common stock. It also applies to common stock owned now or acquired later by the person executing the agreement or for which the person executing the agreement
later acquires the power of disposition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Global Select Market Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares are listed on the Nasdaq Global Select Market under the symbol &#147;SGMO.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Price Stabilization, Short Positions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until the distribution of the shares is completed, SEC rules may limit underwriters and selling group members from bidding for and purchasing
our common stock. However, the representatives may engage in transactions that stabilize the price of the common stock, such as bids or purchases to peg, fix or maintain that price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the offering, the underwriters may purchase and sell our common stock in the open market. These transactions may include
short sales, purchases on the open market to cover positions created by short sales and stabilizing transactions. Short sales involve the sale by the underwriters of a greater number of shares than they are required to purchase in the offering.
&#147;Covered&#148; short sales are sales made in an amount not greater than the underwriters&#146; option to purchase additional shares described above. The underwriters may close out any covered short position by either exercising their option to
purchase additional shares or purchasing shares in the open market. In determining the source of shares to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the
open market as compared to the price at which they may purchase shares through the option granted to them. &#147;Naked&#148; short sales are sales in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
excess of such option. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters
are concerned that there may be downward pressure on the price of our common stock in the open market after pricing that could adversely affect investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases
of shares of common stock made by the underwriters in the open market prior to the completion of the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar to other purchase
transactions, the underwriters&#146; purchases to cover the syndicate short sales may have the effect of raising or maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a
result, the price of our common stock may be higher than the price that might otherwise exist in the open market. The underwriters may conduct these transactions on the Nasdaq Global Select Market, in the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor any of the underwriters make any
representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our common stock. In addition, neither we nor any of the underwriters make any representation that the
representatives will engage in these transactions or that these transactions, once commenced, will not be discontinued without notice. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Passive Market
Making </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering, underwriters and selling group members may engage in passive market making transactions in
the common stock on the Nasdaq Global Market in accordance with Rule 103 of Regulation M under the Exchange Act during a period before the commencement of offers or sales of common stock and extending through the completion of distribution. A
passive market maker must display its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker&#146;s bid, that bid must then be lowered when specified
purchase limits are exceeded. Passive market making may cause the price of our common stock to be higher than the price that otherwise would exist in the open market in the absence of those transactions. The underwriters and dealers are not required
to engage in passive market making and may end passive market making activities at any time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic Distribution </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the offering, certain of the underwriters or securities dealers may distribute prospectuses by electronic means, such as <FONT
STYLE="white-space:nowrap">e-mail.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of the underwriters and their affiliates have engaged in, and may in the future engage in, investment banking and other commercial
dealings in the ordinary course of business with us or our affiliates. They have received, or may in the future receive, customary fees and commissions for these transactions. Cowen is the sales agent under our ATM Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of their business activities, the underwriters and their affiliates may make or hold a broad array of
investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers. Such investments and securities activities
may involve securities and/or instruments of ours or our affiliates. The underwriters and their affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial
instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>European Economic Area </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to each member state of the European Economic Area, no offer of shares which are the subject of the offering has been, or will be
made to the public in that Member State, other than under the following exemptions under the Prospectus Directive: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Directive), subject to obtaining the prior consent of the Representatives for any such offer; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">in any other circumstances falling within Article 3(2) of the Prospectus Directive, </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">provided
that no such offer of shares referred to in (a)&nbsp;to (c) above shall result in a requirement for the Company or any Representative to publish a prospectus pursuant to Article 3 of the Prospectus Directive, or supplement a prospectus pursuant to
Article 16 of the Prospectus Directive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each person located in a Member State to whom any offer of shares is made or who receives any
communication in respect of an offer of shares, or who initially acquires any shares will be deemed to have represented, warranted, acknowledged and agreed to and with each Representative and the Company that (1)&nbsp;it is a &#147;qualified
investor&#148; within the meaning of the law in that Member State implementing Article 2(1)(e) of the Prospectus Directive; and (2)&nbsp;in the case of any shares acquired by it as a financial intermediary as that term is used in Article 3(2) of the
Prospectus Directive, the shares acquired by it in the offer have not been acquired on behalf of, nor have they been acquired with a view to their offer or resale to, persons in any Member State other than qualified investors, as that term is
defined in the Prospectus Directive, or in circumstances in which the prior consent of the Representatives has been given to the offer or resale; or where shares have been acquired by it on behalf of persons in any Member State other than qualified
investors, the offer of those shares to it is not treated under the Prospectus Directive as having been made to such persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company, the Representatives and their respective affiliates will rely upon the truth and accuracy of the foregoing representations, acknowledgments and agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus has been prepared on the basis that any offer of shares in any Member State will be made pursuant to an exemption under the
Prospectus Directive from the requirement to publish a prospectus for offers of shares. Accordingly any person making or intending to make an offer in that Member State of shares which are the subject of the offering contemplated in this prospectus
may only do so in circumstances in which no obligation arises for the Company or any of the Representatives to publish a prospectus pursuant to Article 3 of the Prospectus Directive in relation to such offer. Neither the Company nor the
Representatives have authorized, nor do they authorize, the making of any offer of shares in circumstances in which an obligation arises for the Company or the Representatives to publish a prospectus for such offer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an &#147;offer of shares to the public&#148; in relation to any ordinary shares in any
Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the ordinary shares to be offered so as to enable an investor to decide to purchase or subscribe the ordinary shares, as the
same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State, the expression &#147;Prospectus Directive&#148; means Directive 2003/71/EC (as amended) and includes any relevant implementing measure
in each Member State. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above selling restriction is in addition to any other selling restrictions set out below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the United Kingdom </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may
only be directed at persons who are &#147;qualified investors&#148; (as defined in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Prospectus Directive)&nbsp;(i) who have professional experience in matters relating to investments falling within Article 19 (5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005, as amended (the &#147;Order&#148;) and/or (ii)&nbsp;who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d)&nbsp;of the Order (all such persons
together being referred to as &#147;relevant persons&#148;). This document must not be acted on or relied on in the United Kingdom by persons who are not relevant persons. In the United Kingdom, any investment or investment activity to which this
document relates is only available to, and will be engaged in with, relevant persons. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Switzerland </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (&#147;SIX&#148;) or on any other stock
exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for
listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to the shares
or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither this document nor any other
offering or marketing material relating to the offering, the Company, the shares have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of shares will not be
supervised by, the Swiss Financial Market Supervisory Authority FINMA (FINMA), and the offer of shares has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes (&#147;CISA&#148;). The investor protection
afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective
Investors in the Dubai International Financial Centre </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement relates to an Exempt Offer in accordance with the
Offered Securities Rules of the Dubai Financial Services Authority (&#147;DFSA&#148;). This prospectus supplement is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered
to, or relied on by, any other person. The DFSA has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus supplement nor taken steps to verify the information set forth
herein and has no responsibility for the prospectus supplement. The shares to which this prospectus supplement relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares offered should conduct their
own due diligence on the shares. If you do not understand the contents of this prospectus supplement you should consult an authorized financial advisor. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Australia </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian Securities and
Investments Commission (&#147;ASIC&#148;), in relation to the offering. This prospectus does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001 (the &#147;Corporations Act&#148;),
and does not purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any offer in Australia of the shares may only be made to persons (the &#147;Exempt Investors&#148;) who are &#147;sophisticated
investors&#148; (within the meaning of section 708(8) of the Corporations Act), &#147;professional investors&#148; (within the meaning of section 708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section
708 of the Corporations Act so that it is lawful to offer the shares without disclosure to investors under Chapter 6D of the Corporations Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares applied for by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12 months after the date of
allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an exemption under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
section 708 of the Corporations Act or otherwise or where the offer is pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring shares must
observe such Australian <FONT STYLE="white-space:nowrap">on-sale</FONT> restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains general information only
and does not take account of the investment objectives, financial situation or particular needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors
need to consider whether the information in this prospectus is appropriate to their needs, objectives and circumstances, and, if necessary, seek expert advice on those matters. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Hong Kong </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to
&#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap.&nbsp;571) of Hong Kong and any rules made under that Ordinance; or (b)&nbsp;in other circumstances which do not result in the document being a
&#147;prospectus&#148; as defined in the Companies Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation or document relating to the securities has been
or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except
if permitted to do so under the securities laws of Hong Kong) other than with respect to securities which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the
Securities and Futures Ordinance and any rules made under that Ordinance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Japan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948, as
amended) and, accordingly, will not be offered or sold, directly or indirectly, in Japan, or for the benefit of any Japanese Person or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or
to any Japanese Person, except in compliance with all applicable laws, regulations and ministerial guidelines promulgated by relevant Japanese governmental or regulatory authorities in effect at the relevant time. For the purposes of this paragraph,
&#147;Japanese Person&#148; shall mean any person resident in Japan, including any corporation or other entity organized under the laws of Japan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Singapore </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other
document or material in connection with the offer or sale, or invitation for subscription or purchase, of <FONT STYLE="white-space:nowrap">Non-CIS</FONT> Securities may not be circulated or distributed, nor may the
<FONT STYLE="white-space:nowrap">Non-CIS</FONT> Securities be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional
investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore (the &#147;SFA&#148;), (ii) to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in accordance with the
conditions specified in Section&nbsp;275, of the SFA, or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where the <FONT STYLE="white-space:nowrap">Non-CIS</FONT> Securities are subscribed or purchased under Section&nbsp;275 of the SFA by a
relevant person which is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals,
each of whom is an accredited investor; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation or the beneficiaries&#146;
rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the <FONT STYLE="white-space:nowrap">Non-CIS</FONT> Securities pursuant to an offer made under
Section&nbsp;275 of the SFA except: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">where no consideration is or will be given for the transfer; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">where the transfer is by operation of law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">as specified in Section&nbsp;276(7) of the SFA; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Canada </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in
National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> <I>Prospectus Exemptions</I> or subsection 73.3(1) of the <I>Securities Act</I> (Ontario), and are permitted clients, as defined in National Instrument
<FONT STYLE="white-space:nowrap">31-103</FONT> <I>Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>. Any resale of the securities must be made in accordance with an exemption from, or in a transaction not subject to, the
prospectus requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a
purchaser with remedies for rescission or damages if this prospectus supplement (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit
prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these
rights or consult with a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 (or, in the case of securities issued or guaranteed by the government of
a <FONT STYLE="white-space:nowrap">non-Canadian</FONT> jurisdiction, section 3A.4) of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> <I>Underwriting Conflicts</I> (NI <FONT STYLE="white-space:nowrap">33-105),</FONT> the
underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom570679_11"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the shares of common stock offered by this prospectus supplement and the accompanying prospectus will be passed upon for us by
Cooley LLP, San Francisco, California. Proskauer Rose LLP, New&nbsp;York, New York, is counsel for the underwriters in connection with this offering. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom570679_12"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our
Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017, and the effectiveness of our internal control over financial reporting as of December&nbsp;31, 2017, as set forth in their reports, which
are incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Ernst&nbsp;&amp; Young LLP&#146;s reports, given on their authority as experts in
accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom570679_13"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus are part of the registration statement on
<FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> we filed with the SEC under the Securities Act and do not contain all the information set forth or incorporated by reference in the registration statement. Whenever a reference is made in this
prospectus supplement or the accompanying prospectus to any of our contracts, agreements or other documents, the reference may not be complete and you should refer to the exhibits that are a part of the registration statement or the exhibits to the
reports or other documents incorporated by reference into this prospectus supplement and the accompanying prospectus for a copy of such contract, agreement or other document. Because we are subject to the information and reporting requirements of
the Exchange Act, we file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC&#146;s website at http://<I>www.sec.gov</I>. You may also
read and copy any document we file at the SEC&#146;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-SEC-0330</FONT></FONT></FONT> for further information on the operation of the Public Reference Room. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom570679_14"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; information from other documents that we file with it, which means that we can
disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus supplement and the accompanying prospectus. Information in this prospectus supplement
supersedes information incorporated by reference that we filed with the SEC prior to the date of this prospectus supplement, while information that we file later with the SEC will automatically update and supersede the information in this prospectus
supplement and the accompanying prospectus. We incorporate by reference the documents listed below and any future filings (other than current reports furnished under Item 2.02 or Item 7.01 of
<FONT STYLE="white-space:nowrap">Form&nbsp;8-K&nbsp;and</FONT> exhibits filed on such form that are related to such items) we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus supplement
and prior to the termination of the offering of the common stock covered by this prospectus supplement (Commission File <FONT STYLE="white-space:nowrap">No.&nbsp;000-30171):</FONT> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017, which was filed with the SEC on March&nbsp;1, 2018, as amended by Form
<FONT STYLE="white-space:nowrap">10-K/A,</FONT> which was filed with the SEC on April&nbsp;24, 2018; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the information specifically incorporated by reference into our annual report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;for</FONT> the year ended December&nbsp;31, 2017 from our revised definitive proxy
statement relating to our 2018 annual meeting of stockholders, which was filed with the SEC on April&nbsp;24, 2018; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our current reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> which were filed with the SEC on January&nbsp;3, 2018, February&nbsp;22, 2018 (except for the information furnished under Item 2.02 thereof and the
accompanying exhibit 99.1), March&nbsp;23, 2018 and April&nbsp;17, 2018; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the description of our common stock in our registration statement on Form <FONT STYLE="white-space:nowrap">8-A,</FONT> which was filed with the SEC on March&nbsp;31, 2000, including all amendments and reports filed for
the purpose of updating such description. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will furnish without charge to each person, including any beneficial owner, to
whom a prospectus is delivered, upon written or oral request, a copy of any or all of the documents incorporated by reference, including exhibits to these documents. Any such request may be made by writing or telephoning us at the following address
or phone number: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Sangamo Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">501 Canal Boulevard </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Richmond,
California 94804 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(510) <FONT STYLE="white-space:nowrap">970-6000</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Investor Relations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prospectus </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g573964g85h57.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt
Securities </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:14pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to
time, we or selling securityholders may offer and sell any combination of the securities described in this prospectus, either individually or in combination with other securities. We or selling securityholders may also offer common stock or
preferred stock upon conversion of debt securities, common stock upon conversion of preferred stock, or common stock, preferred stock or debt securities upon the exercise of warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each time we sell securities pursuant to this prospectus, we will provide the specific terms of these offerings and securities in one or more
supplements to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related free writing prospectus may also add, update or change
information contained in this prospectus. You should carefully read this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as the documents incorporated by reference, before buying any of the
securities being offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The Nasdaq Global Select Market under the trading symbol &#147;SGMO.&#148; On
April&nbsp;23, 2018, the last reported sale price of our common stock was $18.15 per share. The applicable prospectus supplement will contain information, where applicable, as to other listings, if any, on The Nasdaq Global Select Market or other
securities exchange of the securities covered by the applicable prospectus supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Investing in our securities involves a high
degree of risk. You should review carefully the risks and uncertainties described under the heading &#147;Risk Factors&#148; contained in the applicable prospectus supplement and in any free writing prospectuses we have authorized for use in
connection with a specific offering, and under similar headings in the documents that are incorporated by reference into this prospectus. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>This prospectus may not be used to consummate a sale of securities unless accompanied by a prospectus supplement. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities may be sold directly to investors, through agents designated from time to time or to or through underwriters or dealers, on a
continuous or delayed basis. For additional information on the methods of sale, you should refer to the section entitled &#147;Plan of Distribution&#148; in this prospectus. If any agents, underwriters or dealers are involved in the sale of any
securities with respect to which this prospectus is being delivered, the names of such agents, underwriters or dealers and any applicable fees, commissions, discounts and over-allotment options will be set forth in a prospectus supplement. The price
to the public of such securities and the net proceeds we expect to receive from such sale will also be set forth in a prospectus supplement. Unless the applicable prospectus supplement provides otherwise, we will not receive any proceeds from the
sale of securities by selling securityholders. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has
approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The date of this
prospectus is April 24, 2018. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc573964_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc573964_2">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc573964_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc573964_4">FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc573964_5">FINANCIAL RATIOS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc573964_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc573964_7">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc573964_8">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc573964_9">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc573964_10">LEGAL OWNERSHIP OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc573964_11">SELLING SECURITYHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc573964_12">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc573964_13">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc573964_14">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc573964_15">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc573964_16">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc573964_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the Securities and
Exchange Commission, or SEC, utilizing a &#147;shelf&#148; registration process. Under this shelf registration process, we or selling securityholders may offer and sell shares of our common stock and preferred stock, various series of debt
securities and/or warrants to purchase any of such securities, either individually or in combination with other securities, in one or more offerings. There is no limit on the aggregate amount of the securities that we or selling securityholders may
offer pursuant to the registration statement of which this prospectus is a part. This prospectus provides you with a general description of the securities we or selling securityholders may offer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each time we or selling securityholders offer securities under this prospectus, we will provide a prospectus supplement that will contain more
specific information about the terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement and any related
free writing prospectus that we may authorize to be provided to you may also add, update or change any of the information contained in this prospectus or in the documents that we have incorporated by reference into this prospectus. We urge you to
read carefully this prospectus, any applicable prospectus supplement and any free writing prospectuses we have authorized for use in connection with a specific offering, together with the information incorporated herein by reference as described
under the heading &#147;Incorporation of Certain Information by Reference,&#148; before buying any of the securities being offered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>This prospectus may not be used to consummate a sale of securities unless it is accompanied by a prospectus supplement. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained in, or incorporated by reference into, this prospectus and the applicable prospectus
supplement, along with the information contained in any free writing prospectuses we have authorized for use in connection with a specific offering. We have not authorized anyone to provide you with different or additional information. This
prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information appearing in this prospectus, any applicable prospectus supplement and any related free writing prospectus is accurate only as
of the date on the front of the document and any information we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus, the applicable
prospectus supplement or any related free writing prospectus, or any sale of a security. Our business, financial condition, results of operations and prospects may have changed since those dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the
actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as
exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the section entitled &#147;Where You Can Find More Information.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context indicates otherwise, as used in this prospectus, the terms &#147;Sangamo,&#148; &#147;we,&#148; &#147;us&#148; and
&#147;our&#148; refer to Sangamo Therapeutics,&nbsp;Inc., a Delaware corporation, and its subsidiaries on a consolidated basis. SANGAMO<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, SANGAMO THERAPEUTICS<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Better Therapeutics By Design<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, ZFP Therapeutic<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Engineering Genetic Cures<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, and Pioneering Genetic Cures<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> are our registered trademarks in the United States. All other trademarks or trade names referred to in this
prospectus and any prospectus supplement are the property of their respective owners. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc573964_2"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information contained elsewhere in this prospectus or incorporated by reference in this prospectus, and
does not contain all of the information that you need to consider in making your investment decision. You should carefully read the entire prospectus, the applicable prospectus supplement and any related free writing prospectus, including the risks
of investing in our securities discussed under the heading &#147;Risk Factors&#148; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by
reference into this prospectus. You should also carefully read the information incorporated by reference into this prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus is a part.
</I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sangamo Therapeutics, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
are a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients&#146; lives using our industry-leading platform technologies in genome editing, gene therapy, gene regulation
and cell therapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of
proteins found in humans. We have used our knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to
specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of
developing this platform, we have accrued significant scientific, manufacturing and regulatory capabilities and <FONT STYLE="white-space:nowrap">know-how</FONT> that are generally applicable in the broader field of gene therapy and have capitalized
this knowledge into a conventional gene therapy platform based on adeno-associated viral vector cDNA gene transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated
in June 1995 in the state of Delaware and in January 2017, we changed our name from &#147;Sangamo BioSciences, Inc.&#148; to &#147;Sangamo Therapeutics, Inc.&#148; Our website is <I>www.sangamo.com</I>. Information found on, or accessible through,
our website is not a part of, and is not incorporated into, this prospectus, and you should not consider it part of this prospectus or part of any prospectus supplement. Our website address is included in this prospectus as an inactive textual
reference only. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Description of Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We or selling securityholders may offer shares of our common stock and preferred stock, various series of debt securities and/or warrants to
purchase any of such securities, either individually or in combination with other securities, from time to time under this prospectus, together with the applicable prospectus supplement and any related free writing prospectus, at prices and on terms
to be determined by market conditions at the time of any offering. This prospectus provides you with a general description of the securities we or selling securityholders may offer. Each time we or selling securityholders offer a type or series of
securities under this prospectus, we will provide a prospectus supplement that will describe the specific amounts, prices and other important terms of the securities, including, to the extent applicable: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">designation or classification; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">aggregate principal amount or aggregate offering price; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maturity date, if applicable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">original issue discount, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">rates and times of payment of interest or dividends, if any; </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">redemption, conversion, exercise, exchange or sinking fund terms, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ranking; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictive covenants, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">voting or other rights, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conversion or exchange prices or rates, if any, and, if applicable, any provisions for changes to or adjustments in the conversion or exchange prices or rates and in the securities or other property receivable upon
conversion or exchange; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">material or special U.S. federal income tax considerations, if any. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus
supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change any of the information contained in this prospectus or in the documents we have incorporated by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We or selling securityholders may sell the securities directly to investors or to or through agents, underwriters or dealers. If we or selling
securityholders do offer securities to or through agents or underwriters, we will include in the applicable prospectus supplement: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the names of those agents or underwriters; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; applicable fees, discounts and commissions to be paid to them; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; details regarding over-allotment or other options, if any; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the net proceeds to us, if any. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Common Stock</I>. We may issue shares of our common stock from time to time. The holders of common stock are entitled to one vote per share
on all matters to be voted on by the stockholders. Subject to the preferences of any outstanding shares of preferred stock, the holders of common stock are entitled to receive ratably any dividends our board of directors declares out of funds
legally available for the payment of dividends. If we are liquidated, dissolved or wound up, the holders of common stock are entitled to share pro rata all assets remaining after payment of liabilities and liquidation preferences of any outstanding
shares of preferred stock. Holders of common stock have no preemptive rights or rights to convert their common stock into any other securities. There are no redemption or sinking fund provisions applicable to the common stock. In this prospectus, we
have summarized certain general features of the common stock under the heading &#147;Description of Capital Stock&#151;Common Stock.&#148;&nbsp;We urge you, however, to read the applicable prospectus supplement (and any related free writing
prospectus that we may authorize to be provided to you) related to any common stock being offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Preferred Stock.</I> We may issue
shares of our preferred stock from time to time, in one or more series. Under our seventh amended and restated certificate of incorporation, as amended, our board of directors has the authority to designate up to 5,000,000 shares of preferred stock
in one or more series and determine or alter the designation, rights, preferences, privileges and restrictions granted to or imposed upon any series of preferred stock, any or all of which may be greater than the rights of the common stock. If we
sell any new series of preferred stock under this prospectus and any applicable prospectus supplement, our board of directors will determine the rights, preferences and privileges of the preferred stock being offered, as well as the qualifications,
limitations or restrictions thereof, including dividend rights, conversion rights, voting rights, preemptive rights, terms of redemption or repurchase, liquidation preferences, sinking fund terms and the number of shares constituting any series or
the designation of any series. Preferred stock may be convertible into our common stock or other securities of ours, or may be exchangeable for debt securities. Conversion may be mandatory or at the holder&#146;s option and would be at prescribed
conversion rates. We will file as an exhibit to the registration </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of the certificate of designation that describes the terms of the
series of preferred stock being offered before the issuance of the related series of preferred stock. In this prospectus, we have summarized certain general features of the preferred stock under the heading &#147;Description of Capital
Stock&#151;Preferred Stock.&#148; We urge you, however, to read the applicable prospectus supplement (and any related free writing prospectus that we may authorize to be provided to you) related to the series of preferred stock being offered, as
well as the complete certificate of designation that contains the terms of the applicable series of preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Debt
Securities.</I>&nbsp;We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. Convertible or exchangeable debt securities will be convertible into or
exchangeable for our common stock or our other securities. Conversion or exchange may be mandatory or optional (at our option or the holders&#146; option) and would be at prescribed conversion or exchange prices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The debt securities will be issued under an indenture that we will enter into with a national banking association or other eligible party, as
trustee. In this prospectus, we have summarized certain general features of the debt securities under the heading &#147;Description of Debt Securities.&#148; We urge you, however, to read the applicable prospectus supplement (and any related free
writing prospectus that we may authorize to be provided to you) related to the series of debt securities being offered, as well as the complete indenture and any supplemental indentures that contain the terms of the debt securities. We have filed
the form of indenture as an exhibit to the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the
registration statement of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Warrants.</I>&nbsp;We may issue warrants for the purchase of common stock, preferred stock and/or debt securities in one or more series. We
may issue warrants independently or in combination with common stock, preferred stock and/or debt securities offered by any prospectus supplement. In this prospectus, we have summarized certain general features of the warrants under the heading
&#147;Description of Warrants.&#148; We urge you, however, to read the applicable prospectus supplement (and any related free writing prospectus that we may authorize to be provided to you) related to the particular series of warrants being offered,
as well as the form of warrant and/or the warrant agreement and warrant certificate, as applicable, that contain the terms of the warrants. We have filed the forms of the warrant agreements and forms of warrant certificates containing the terms of
the warrants that we may offer as exhibits to the registration statement of which this prospectus is a part. We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from reports
that we file with the SEC, the form of warrant and/or the warrant agreement and warrant certificate, as applicable, that contain the terms of the particular series of warrants we are offering, and any supplemental agreements, before the issuance of
such warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Warrants may be issued under a warrant agreement that we enter into with a warrant agent. We will indicate&nbsp;the name
and address of the warrant agent, if any, in the applicable prospectus supplement relating to a particular series of warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selling Securityholders
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling securityholders are persons or entities that, directly or indirectly, have acquired or will from time to time acquire from us,
our securities. Information about selling securityholders, if any, will be set forth in a prospectus supplement. See &#147;Selling Securityholders&#148; on page 26 of this prospectus. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of Proceeds </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as described in any applicable prospectus supplement or in any free writing prospectuses we have authorized for use in connection with a
specific offering, we intend to use the net proceeds from the sale of the securities under this prospectus for working capital and other general corporate purposes, including support for our continuing research and development of our genomic therapy
product candidates and research programs, clinical trials and business development activities. See &#147;Use of Proceeds&#148; on page 8 of this prospectus. Unless the applicable prospectus supplement provides otherwise, we will not receive any of
the proceeds from the sale of our securities by selling securityholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Global Select Market Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The Nasdaq Global Select Market under the symbol &#147;SGMO.&#148; </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc573964_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our securities involves a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully
the risks and uncertainties described under the heading &#147;Risk Factors&#148; contained in the applicable prospectus supplement and any related free writing prospectus, and described under the section entitled &#147;Risk Factors&#148; contained
in our current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on April 17, 2018, as well as any amendments thereto reflected in subsequent filings with the SEC, and in our other filings that are incorporated by
reference into this prospectus in their entirety, together with other information in this prospectus, the documents incorporated by reference and any free writing prospectus that we may authorize for use in connection with a specific offering. The
risks described in these documents are not the only ones we face, but those that we consider to be material. There may be other unknown or unpredictable economic, business, competitive, regulatory or other factors that could have material adverse
effects on our future results. Past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results or trends in future periods. If any of these risks actually occurs, our
business, financial condition, results of operations or cash flow could be seriously harmed. This could cause the trading price of our securities to decline, resulting in a loss of all or part of your investment. Please also carefully read the
section below entitled &#147;Forward-Looking Statements.&#148; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc573964_4"></A>FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and any accompanying prospectus supplement, as well as the documents incorporated by reference in this prospectus or any
accompanying prospectus supplement, contain &#147;forward-looking statements&#148; within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of the Securities Exchange Act of 1934,
as amended, or the Exchange Act. These statements relate to future events or to our future operating or financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or
achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements may include, but are not limited to, statements about: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our strategy; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">anticipated product candidate development and potential commercialization of any resulting products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the initiation, scope, rate of progress, enrollment, anticipated results and timing of our preclinical studies and clinical trials and those of our collaborators or strategic partners; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the therapeutic and commercial potential of, and the ability of Sangamo and our collaborators or strategic partners to advance the development of, product candidates using our ZFP technology platform, including our
ability to effectively deliver our ZFNs and ZFP TFs to produce a beneficial therapeutic effect; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to establish and maintain collaborative, licensing and other similar arrangements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">anticipated revenues from existing and new collaborations and the timing thereof; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our research and development and other expenses; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain adequate preclinical and clinical supplies of our product candidates from current and potential new suppliers and manufacturers; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the ability of Sangamo and our collaborators or strategic partners to obtain and maintain regulatory approvals for product candidates using our ZFP technology platform; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to comply with, and the impact of, regulatory requirements, obligations and restrictions on our business; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others, including our ability to obtain rights to the gene transfer technologies
required to develop and commercialize our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our estimates regarding the sufficiency of our cash resources and our expenses, capital requirements and need for additional financing, and our ability to obtain additional financing; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to manage the growth of our business; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our projected operating and financial performance; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our operational and legal risks; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our intended use of the net proceeds from offerings of our securities under this prospectus; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our plans, objectives, expectations and intentions and any other statements that are not historical facts. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some cases, you can identify forward-looking statements by terms such as &#147;anticipates,&#148; &#147;believes,&#148; &#147;could,&#148;
&#147;estimates,&#148; &#147;expects,&#148; &#147;may,&#148; &#147;plans,&#148; &#147;potential,&#148; &#147;predicts,&#148; &#147;projects,&#148; &#147;should,&#148; &#147;would,&#148; &#147;will&#148; and similar expressions intended to identify
forward-looking statements. These statements reflect our current views with respect to future events, are based on assumptions and are subject to risks and uncertainties. Given these risks and uncertainties, you should not place undue reliance on
these forward-looking statements. We discuss in greater detail, and incorporate by reference into this prospectus in their entirety, many of these risks and uncertainties under the heading &#147;Risk Factors&#148; contained in the applicable
prospectus supplement, in any free writing prospectus we may authorize for use in connection with a specific offering, and in our most recent annual report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> in our most recent quarterly report on
Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> as well as any amendments thereto reflected in subsequent filings with the SEC, and in our other filings that are incorporated by reference into this prospectus. Also, these forward-looking
statements represent our estimates and assumptions only as of the date of the document containing the applicable statement. Unless required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new
information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. You should read this prospectus, the applicable
prospectus supplement, together with the documents we have filed with the SEC that are incorporated by reference and any free writing prospectus we have authorized for use in connection with a specific offering completely and with the understanding
that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in the foregoing documents by these cautionary statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc573964_5"></A>FINANCIAL RATIOS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our ratio of earnings to fixed charges and the ratio of our earnings to combined fixed charges and preferred
stock dividends to earnings for each of the periods presented. Our net losses were insufficient to cover fixed charges and combined fixed charges and preferred stock dividends for each of the periods presented. Because of these deficiencies, the
ratio information is not applicable for those periods. The extent to which earnings were insufficient to cover fixed charges and combined fixed charges and preferred stock dividends for those periods is shown below. Amounts shown are in thousands,
except for ratios. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ratio of earnings to fixed charges(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ratio of earnings to combined fixed charges and preferred stock dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deficiency of earnings available to cover fixed charges</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,624</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,417</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(46,425</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(71,672</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(54,568</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deficiency of earnings available to cover combined fixed charges and preferred stock
dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,624</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,417</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(46,425</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(71,672</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(54,568</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">&#147;Earnings&#148; are the sum of loss from continuing operations before income taxes plus fixed charges. &#147;Fixed charges&#148; consist of interest expense and interest capitalized related to <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">build-to-suit</FONT></FONT> leases. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc573964_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as described in any applicable prospectus supplement or in any free writing prospectuses we have authorized for use in connection with
a specific offering, we intend to use the net proceeds from the sale of the securities under this prospectus for working capital and other general corporate purposes, including support for our continuing research and development of our genomic
therapy product candidates and research programs, clinical trials and business development activities. We will set forth in the applicable prospectus supplement our intended use for the net proceeds received from the sale of any securities. Pending
the use of the net proceeds, we intend to invest the net proceeds in short-term, investment-grade, interest-bearing securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless
the applicable prospectus supplement provides otherwise, we will not receive any of the proceeds from the sale of our securities by selling securityholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc573964_7"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, our seventh amended and restated certificate of incorporation, as amended, or the Restated Certificate,
authorizes us to issue 160,000,000 shares of common stock, par value $0.01 per share, and 5,000,000 shares of preferred stock, par value $0.01 per share. As of March&nbsp;31, 2018, 87,041,208&nbsp;shares of common stock were outstanding and no
shares of our preferred stock were outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary description of our capital stock is based on the provisions of the
Restated Certificate, our second amended and restated bylaws, as amended, or our Bylaws, and the applicable provisions of the General Corporation Law of the State of Delaware, or DGCL. This information may not be complete in all respects and is
qualified entirely by reference to the provisions of the Restated Certificate, our Bylaws and the DGCL. For information on how to obtain copies of the Restated Certificate and our Bylaws, which are exhibits to the registration statement of which
this prospectus forms a part, see &#147;Where You Can Find More Information.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of common stock are entitled to one vote per share on all matters to be voted on by the stockholders. Stockholders have no
cumulative voting rights. Subject to the preferences of any outstanding shares of preferred stock, the holders of common stock are entitled to receive ratably any dividends our board of directors declares out of funds legally available for the
payment of dividends. If we are liquidated, dissolved or wound up, the holders of common stock are entitled to share pro rata all assets remaining after payment of liabilities and liquidation preferences of any outstanding shares of preferred stock.
Holders of common stock have no preemptive rights or rights to convert their common stock into any other securities. There are no redemption or sinking fund provisions applicable to the common stock.&nbsp;When we issue shares of common stock under
this prospectus, the shares will be fully paid and nonassessable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional shares of authorized common stock may be issued, as
authorized by our board of directors from time to time, without stockholder approval, except as may be required by applicable stock exchange requirements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Restated
Certificate, our board of directors has the authority, without further action by the stockholders, to issue shares of preferred stock in one or more series. Our board of directors also has the authority to determine or alter the designation, rights,
preferences, privileges and restrictions granted to or imposed upon any unissued series of preferred stock, any or all of which may be greater than the rights of the common stock. Our board of directors, without stockholder approval, may issue
preferred stock with voting, conversion or other rights that are superior to the voting and other rights of the holders of common stock. The issuance of preferred stock may have the effect of delaying, deferring or preventing a change of control of
Sangamo without further action by the stockholders, and may have the effect of delaying or preventing changes in management of Sangamo. In addition, the issuance of preferred stock may have the effect of decreasing the market price of the common
stock and may adversely affect the voting power of holders of common stock and reduce the likelihood that common stockholders will receive dividend payments and payments upon liquidation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors will determine the rights, preferences, privileges and restrictions of the preferred stock of each series that we sell
under this prospectus and applicable prospectus supplements in the certificate of designation relating to that series. We will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from
reports that we file with the SEC, the form of the certificate of designation that describes the terms of the series of preferred stock that we are offering before the issuance of the related series of preferred stock. This description will include:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the title and stated value; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of shares we are offering; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the liquidation preference per share; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the purchase price per share; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the dividend rate per share, dividend period and payment dates and method of calculation for dividends; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether dividends will be cumulative or <FONT STYLE="white-space:nowrap">non-cumulative</FONT> and, if cumulative, the date from which dividends will accumulate; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our right, if any, to defer payment of dividends and the maximum length of any such deferral period; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the procedures for any auction and remarketing, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the provisions for a sinking fund, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those redemption and repurchase rights; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any listing of the preferred stock on any securities exchange or market; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the preferred stock will be convertible into our common stock or other securities of ours, including warrants, and, if applicable, the conversion period, the conversion price, or how it will be calculated, and
under what circumstances it may be adjusted; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the preferred stock will be exchangeable for debt securities, and, if applicable, the exchange period, the exchange price, or how it will be calculated, and under what circumstances it may be adjusted;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">voting rights, if any, of the preferred stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">preemption rights, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on transfer, sale or other assignment, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a discussion of any material or special United States federal income tax considerations applicable to the preferred stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the relative ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any limitations on issuances of any class or series of preferred stock ranking senior to or on a parity with the series of preferred stock being issued as to dividend rights and rights if we liquidate, dissolve or wind
up our affairs; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other specific terms, rights, preferences, privileges, qualifications or restrictions of the preferred stock. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When we issue shares of preferred stock under this prospectus, the shares will be fully paid and nonassessable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we specify otherwise in the applicable prospectus supplement, the preferred stock will rank, with respect to dividends and upon our
liquidation, dissolution or winding up: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">senior to all classes or series of our common stock and to all of our equity securities ranking junior to the preferred stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on a parity with all of our equity securities the terms of which specifically provide that the equity securities rank on a parity with the preferred stock; and </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">junior to all of our equity securities the terms of which specifically provide that the equity securities rank senior to the preferred stock. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;equity securities&#148; does not include convertible debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The General Corporation Law of the State of Delaware, the state of our incorporation, provides that the holders of preferred stock will have
the right to vote separately as a class on any proposal involving fundamental changes in the rights of holders of that preferred stock. This right is in addition to any voting rights that may be provided for in the applicable certificate of
designation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Antitakeover Effects of Provisions of Charter Documents and Delaware Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Charter Documents</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As noted
above, our board of directors, without stockholder approval, has the authority under our Restated Certificate to issue preferred stock with rights superior to the rights of the holders of common stock. As a result, the issuance of preferred stock
may have the effect of delaying, deferring or preventing a change of control of Sangamo without further action by the stockholders and may adversely affect the voting and other rights of the holders of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Restated Certificate also requires that any action required or permitted to be taken by our stockholders must be effected at a duly called
annual or special meeting of the stockholders and may not be effected by a consent in writing. Our Bylaws provide that a special meeting of the stockholders may be called only by the chairman of our board or our president and shall be called by the
chairman of our board, our president or our secretary at the request in writing of a majority of the board of directors. These provisions may have the effect of delaying, deferring or preventing a change in control and may also delay or prevent
changes in management of Sangamo, which could have an adverse effect on the market price of our stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These and other provisions are
intended to enhance the likelihood of continued stability in the composition of our board of directors and to discourage certain types of transactions that may involve an actual or threatened change of control. However, such provisions could have
the effect of discouraging others from making tender offers for our shares and, as a consequence, such provisions also may inhibit fluctuations in the market price of our shares that could result from actual or rumored takeover attempts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Section&nbsp;203 of the General Corporation Law of the State of Delaware </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to Section&nbsp;203 of the DGCL which regulates acquisitions of some Delaware corporations. In general, Section&nbsp;203
prohibits, with some exceptions, a publicly held Delaware corporation such as us from engaging in a &#147;business combination&#148; with an &#147;interested stockholder&#148; for a period of three years following the time that the stockholder
became an interested stockholder, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prior to the time the stockholder became an interested stockholder, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an
interested stockholder; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the
transaction commenced, excluding for purposes of determining the number of shares outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned by (a)&nbsp;persons who are directors and also officers and
(b)&nbsp;employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at or subsequent to the time the stockholder became an interested stockholder, the business combination is
approved by the board and authorized at an annual or special meeting of stockholders, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
and not by written consent, by the affirmative vote of at least 66<SUP STYLE="vertical-align:top">&nbsp;2</SUP>&#8260;<SUB STYLE="vertical-align:bottom">3</SUB>% of the outstanding voting stock
which is not owned by the interested stockholder. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 of the DGCL generally defines a &#147;business
combination&#148; to include any of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any merger or consolidation involving the corporation and the interested stockholder; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any sale, transfer, pledge or other disposition involving the interested stockholder (in one transaction or a series of transactions) of assets of the corporation having an aggregate market value equal to 10% or more of
the aggregate market value of either all of the assets of the corporation or its outstanding stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">subject to exceptions, any transaction involving the corporation that has the effect, directly or indirectly, of increasing the proportionate share of the stock or any class or series of the corporation beneficially
owned by the interested stockholder; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the receipt by the interested stockholder of the benefit, directly or indirectly (except proportionately as a stockholder of such corporation), of any loans, advances, guarantees, pledges or other financial benefits,
other than certain benefits set forth in Section&nbsp;203, provided by or through the corporation. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general,
Section&nbsp;203 defines an &#147;interested stockholder&#148; as an entity or person who, together with the person&#146;s affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested
stockholder status did own, 15% or more of the outstanding voting stock of the corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 of the DGCL could depress
our stock price and delay, discourage or prohibit transactions not approved in advance by our board of directors, such as takeover attempts that might otherwise involve the payment to our stockholders of a premium over the market price of our common
stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock is Computershare, Inc. Its address is 250 Royall Street, Canton, MA 02021and its
telephone number is (781) <FONT STYLE="white-space:nowrap">575-3951.</FONT> The transfer agent for any series of preferred stock that we or selling securityholders may offer under this prospectus will be named and described in the applicable
prospectus supplement for that series. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing on The Nasdaq Global Select Market </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The Nasdaq Global Select Market under the symbol &#147;SGMO.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc573964_8"></A>DESCRIPTION OF DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated
convertible debt. While the terms we have summarized below will apply generally to any debt securities that we may offer under this prospectus, we will describe the particular terms of any debt securities that we or selling securityholders may offer
in more detail in the applicable prospectus supplement. The terms of any debt securities offered under a prospectus supplement may differ from the terms described below. Unless the context requires otherwise, whenever we refer to the indenture, we
also are referring to any supplemental indentures that specify the terms of a particular series of debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will issue the
debt securities under the indenture that we will enter into with the trustee named in the indenture. The indenture will be qualified under the Trust Indenture Act of 1939, as amended, or the Trust Indenture Act. We have filed the form of indenture
as an exhibit to the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration
statement of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
summary of material provisions of the debt securities and the indenture is subject to, and qualified in its entirety by reference to, all of the provisions of the indenture applicable to a particular series of debt securities. We urge you to read
the applicable prospectus supplements and any related free writing prospectuses related to the debt securities that we or selling securityholders may offer under this prospectus, as well as the complete indenture that contains the terms of the debt
securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture
does not limit the amount of debt securities that we may issue. It provides that we may issue debt securities up to the principal amount that we may authorize and may be in any currency or currency unit that we may designate. Except for the
limitations on consolidation, merger and sale of all or substantially all of our assets contained in the indenture, the terms of the indenture do not contain any covenants or other provisions designed to give holders of any debt securities
protection against changes in our operations, financial condition or transactions involving us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue the debt securities issued
under the indenture as &#147;discount securities,&#148; which means they may be sold at a discount below their stated principal amount. These debt securities, as well as other debt securities that are not issued at a discount, may be issued with
&#147;original issue discount,&#148; or OID, for U.S. federal income tax purposes because of interest payment and other characteristics or terms of the debt securities. Material U.S. federal income tax considerations applicable to debt securities
issued with OID will be described in more detail in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will describe in the applicable prospectus
supplement the terms of the series of debt securities being offered, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the title of the series of debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any limit upon the aggregate principal amount that may be issued; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the maturity date or dates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the form of the debt securities of the series; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the applicability of any guarantees; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the debt securities rank as senior debt, senior subordinated debt, subordinated debt or any combination thereof, and the terms of any subordination; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if the price (expressed as a percentage of the aggregate principal amount thereof) at which such debt securities will be issued is a price other than the principal amount thereof, the portion of the principal amount
thereof payable upon declaration of acceleration of the maturity thereof, or if applicable, the portion of the principal amount of such debt securities that is convertible into another security or the method by which any such portion shall be
determined; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the interest rate or rates, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue, the dates interest will be payable and the regular record dates for interest
payment dates or the method for determining such dates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our right, if any, to defer payment of interest and the maximum length of any such deferral period; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if applicable, the date or dates after which, or the period or periods during which, and the price or prices at which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional
redemption provisions and the terms of those redemption provisions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the date or dates, if any, on which, and the price or prices at which we are obligated, pursuant to any mandatory sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder&#146;s option to
purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple thereof; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any and all terms, if applicable, relating to any auction or remarketing of the debt securities of that series and any security for our obligations with respect to such debt securities and any other terms which may be
advisable in connection with the marketing of debt securities of that series; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the debt securities of the series shall be issued in whole or in part in the form of a global security or securities; the terms and conditions, if any, upon which such global security or securities may be
exchanged in whole or in part for other individual securities; and the depositary for such global security or securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if applicable, the provisions relating to conversion or exchange of any debt securities of the series and the terms and conditions upon which such debt securities will be so convertible or exchangeable, including the
conversion or exchange price, as applicable, or how it will be calculated and may be adjusted, any mandatory or optional (at our option or the holders&#146; option) conversion or exchange features, the applicable conversion or exchange period and
the manner of settlement for any conversion or exchange; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if other than the full principal amount thereof, the portion of the principal amount of debt securities of the series which shall be payable upon declaration of acceleration of the maturity thereof; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions to or changes in the covenants applicable to the particular debt securities being issued, including, among others, the consolidation, merger or sale covenant; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions to or changes in the events of default with respect to the securities and any change in the right of the trustee or the holders to declare the principal, premium, if any, and interest, if any, with respect to
such securities to be due and payable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions to or changes in or deletions of the provisions relating to covenant defeasance and legal defeasance; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions to or changes in the provisions relating to satisfaction and discharge of the indenture; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions to or changes in the provisions relating to the modification of the indenture both with and without the consent of holders of debt securities issued under the indenture; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the currency of payment of debt securities if other than U.S. dollars and the manner of determining the equivalent amount in U.S. dollars; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether interest will be payable in cash or additional debt securities at our or the holders&#146; option and the terms and conditions upon which the election may be made; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms and conditions, if any, upon which we will pay amounts in addition to the stated interest, premium, if any and principal amounts of the debt securities of the series to any holder that is not a &#147;United
States person&#148; for federal tax purposes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any restrictions on transfer, sale or assignment of the debt securities of the series; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, any other additions or changes in the provisions of the indenture, and any terms that may be required by us or
advisable under applicable laws or regulations. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conversion or Exchange Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will set forth in the applicable prospectus supplement the terms on which a series of debt securities may be convertible into or
exchangeable for our common stock or our other securities. We will include provisions as to settlement upon conversion or exchange and whether conversion or exchange is mandatory, at the option of the holder or at our option. We may include
provisions pursuant to which the number of shares of our common stock or our other securities that the holders of the series of debt securities receive would be subject to adjustment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidation, Merger or Sale </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we
provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the indenture will not contain any covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of
our assets as an entirety or substantially as an entirety. However, any successor to or acquirer of such assets (other than a subsidiary of ours) must assume all of our obligations under the indenture or the debt securities, as appropriate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default under the Indenture </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the following are events of
default under the indenture with respect to any series of debt securities that we may issue: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if we fail to pay any installment of interest on any series of debt securities, as and when the same shall become due and payable, and such default continues for a period of 90 days; provided, however, that a valid
extension of an interest payment period by us in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of interest for this purpose; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if we fail to pay the principal of, or premium, if any, on any series of debt securities as and when the same shall become due and payable whether at maturity, upon redemption, by declaration or otherwise, or in any
payment required by any sinking or analogous fund established with respect to such series; provided, however, that a valid extension of the maturity of such debt securities in accordance with the terms of any indenture supplemental thereto shall not
constitute a default in the payment of principal or premium, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if we fail to observe or perform any other covenant or agreement contained in the debt securities or the indenture, other than a covenant specifically relating to another series of debt securities, and our failure
continues for 90&nbsp;days after we receive written notice of such failure, requiring the same to be remedied and stating that such is a notice of default thereunder, from the trustee or holders of at least 25% in aggregate principal amount of the
outstanding debt securities of the applicable series; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if specified events of bankruptcy, insolvency or reorganization occur. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an event of default with respect to debt securities of any series occurs and is continuing,
other than an event of default specified in the last bullet point above, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing, and to the trustee if
notice is given by such holders, may declare the unpaid principal of, premium, if any, and accrued interest, if any, due and payable immediately. If an event of default specified in the last bullet point above occurs with respect to us, the
principal amount of and accrued interest, if any, of each issue of debt securities then outstanding shall be due and payable without any notice or other action on the part of the trustee or any holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event of
default with respect to the series and its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in accordance with the indenture. Any
waiver shall cure the default or event of default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the indenture, if an event of default under an indenture shall
occur and be continuing, the trustee will be under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have
offered the trustee reasonable indemnity. The holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available
to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the direction so given by the holder is not in conflict with any law or the applicable indenture; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it in personal liability or might be unduly prejudicial to the holders not involved in the proceeding.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of the debt securities of any series will have the right to institute a proceeding under the indenture or to
appoint a receiver or trustee, or to seek other remedies only if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the holder has given written notice to the trustee of a continuing event of default with respect to that series; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have made written request, such holders have offered to the trustee indemnity satisfactory to it against the
costs, expenses and liabilities to be incurred by the trustee in compliance with the request; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount of the outstanding debt securities of that series other conflicting directions within
90&nbsp;days after the notice, request and offer. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These limitations do not apply to a suit instituted by a holder of debt
securities if we default in the payment of the principal, premium, if any, or interest on, the debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will periodically file
statements with the trustee regarding our compliance with specified covenants in the indenture. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification of Indenture; Waiver </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the trustee may change an indenture without the consent of any holders with respect to specific matters: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to cure any ambiguity, defect or inconsistency in the indenture or in the debt securities of any series; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to comply with the provisions described above under the heading &#147;Description of Debt Securities&#151;Consolidation, Merger or Sale;&#148; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to provide for uncertificated debt securities in addition to or in place of certificated debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to add to our covenants, restrictions, conditions or provisions such new covenants, restrictions, conditions or provisions for the benefit of the holders of all or any series of debt securities, to make the occurrence,
or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of default or to surrender any right or power conferred upon us in the indenture; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms, or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to make any change that does not adversely affect the interests of any holder of debt securities of any series in any material respect; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to provide for the issuance of and establish the form and terms and conditions of the debt securities of any series as provided above under the heading &#147;Description of Debt Securities&#151;General&#148; to
establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add to the rights of the holders of any series of debt securities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to evidence and provide for the acceptance of appointment under any indenture by a successor trustee; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust Indenture Act. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the indenture, the rights of holders of a series of debt securities may be changed by us and the trustee with the written
consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, unless we provide otherwise in the prospectus supplement applicable to a particular series of
debt securities, we and the trustee may make the following changes only with the consent of each holder of any outstanding debt securities affected: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">extending the fixed maturity of any debt securities of any series; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any premium payable upon the redemption of any series of any debt securities; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reducing the percentage of debt securities, the holders of which are required to consent to any amendment, supplement, modification or waiver. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Discharge </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each indenture provides that
we can elect to be discharged from our obligations with respect to one or more series of debt securities, except for specified obligations, including obligations to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide for payment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">register the transfer or exchange of debt securities of the series; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">replace stolen, lost or mutilated debt securities of the series; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pay principal of and premium and interest on any debt securities of the series; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintain paying agencies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">hold monies for payment in trust; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recover excess money held by the trustee; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">compensate and indemnify the trustee; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">appoint any successor trustee. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to exercise our rights to be discharged, we must
deposit with the trustee money or government obligations sufficient to pay all the principal of, any premium, if any, and interest on, the debt securities of the series on the dates payments are due. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form, Exchange and Transfer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will
issue the debt securities of each series only in fully registered form without coupons and, unless we provide otherwise in the applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof. The indenture provides
that we may issue debt securities of a series in temporary or permanent global form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company, or DTC, or another depositary named by us and identified in
the applicable prospectus supplement with respect to that series. To the extent the debt securities of a series are issued in global form and as book-entry, a description of terms relating to any book-entry securities will be set forth in the
applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the option of the holder, subject to the terms of the indenture and the limitations applicable to
global securities described in the applicable prospectus supplement, the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like tenor and
aggregate principal amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the indenture and the limitations applicable to global securities set forth in the
applicable prospectus supplement, holders of the debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by us or the
security registrar, at the office of the security registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange, we will impose
no service charge for any registration of transfer or exchange, but we may require payment of any taxes or other governmental charges. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
will name in the applicable prospectus supplement the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities. We may at any time designate additional transfer agents or
rescind the designation of any transfer agent or approve a change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for the debt securities of each series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we elect to redeem the debt securities of any series, we will not be required to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the opening of business 15&nbsp;days before the day of mailing of a notice of redemption of any debt
securities that may be selected for redemption and ending at the close of business on the day of the mailing; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except the unredeemed portion of any debt securities we are redeeming in part. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Concerning the Trustee </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
trustee, other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those duties as are specifically set forth in the applicable indenture. Upon an event of default under an indenture, the
trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs. Subject to this provision, the trustee is under no obligation to exercise any of the powers given it by the indenture at the
request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might incur. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Payment and Paying Agents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any
interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents
designated by us, except that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate in the
applicable prospectus supplement, we will designate the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement any other paying
agents that we initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All money we pay to a paying agent or the trustee for the payment of the principal of or any premium or interest on any debt securities that
remains unclaimed at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us for payment thereof. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture and the debt
securities will be governed by and construed in accordance with the internal laws of the State of New York, except to the extent that the Trust Indenture Act is applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc573964_9"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description, together with the additional information we may include in any applicable prospectus supplement and free writing
prospectus, summarizes the material terms and provisions of the warrants that we may offer under this prospectus, which may consist of warrants to purchase common stock, preferred stock or debt securities and may be issued in one or more series.
Warrants may be offered independently or in combination with common stock, preferred stock or debt securities offered by any prospectus supplement. While the terms we have summarized below will apply generally to any warrants that we may offer under
this prospectus, we will describe the particular terms of any series of warrants in more detail in the applicable prospectus supplement. The following description of warrants will apply to the warrants offered by this prospectus unless we provide
otherwise in the applicable prospectus supplement. The applicable prospectus supplement for a particular series of warrants may specify different or additional terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed forms of the warrant agreements and forms of warrant certificates containing the terms of the warrants that may be offered as
exhibits to the registration statement of which this prospectus is a part. We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form
of warrant and/or the warrant agreement and warrant certificate, as applicable, that contain the terms of the particular series of warrants we are offering, and any supplemental agreements, before the issuance of such warrants. The following
summaries of material terms and provisions of the warrants are subject to, and qualified in their entirety by reference to, all the provisions of the form of warrant and/or the warrant agreement and warrant certificate, as applicable, and any
supplemental agreements applicable to a particular series of warrants that we or selling securityholders may offer under this prospectus. We urge you to read the applicable prospectus supplement related to the particular series of warrants that we
or selling securityholders may offer under this prospectus, as well as any related free writing prospectus, and the complete form of warrant and/or the warrant agreement and warrant certificate, as applicable, and any supplemental agreements, that
contain the terms of the warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will describe in the applicable prospectus supplement the terms of the series of warrants being offered, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the offering price and aggregate number of warrants offered; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the currency for which the warrants may be purchased; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each such security or each principal amount of such security; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon exercise of one warrant and the price at, and currency in which, this principal amount of debt securities may
be purchased upon such exercise; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which these
shares may be purchased upon such exercise; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms of any rights to redeem or call the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the dates on which the right to exercise the warrants will commence and expire; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the manner in which the warrant agreements and warrants may be modified; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a discussion of material or special U.S. federal income tax considerations, if any, of holding or exercising the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms of the securities issuable upon exercise of the warrants; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other specific terms, preferences, rights or limitations of or restrictions on the warrants. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before exercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon such
exercise, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in the case of warrants to purchase debt securities, the right to receive payments of principal of, or premium, if any, or interest on, the debt securities purchasable upon exercise or to enforce covenants in the
applicable indenture; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in the case of warrants to purchase common stock or preferred stock, the right to receive dividends, if any, or payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any.
</TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exercise of Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each warrant will entitle the holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise price
that we describe in the applicable prospectus supplement. The warrants may be exercised as set forth in the prospectus supplement relating to the warrants offered. Unless we otherwise specify in the applicable prospectus supplement, warrants may be
exercised at any time up to the close of business on the expiration date set forth in the prospectus supplement relating to the warrants offered thereby. After the close of business on the expiration date, unexercised warrants will become void. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon receipt of payment and the warrant or warrant certificate, as applicable, properly completed and duly executed at the corporate trust
office of the warrant agent, if any, or any other office, including ours, indicated in the prospectus supplement, we will, as soon as practicable, issue and deliver the securities purchasable upon such exercise. If less than all of the warrants (or
the warrants represented by such warrant certificate) are exercised, a new warrant or a new warrant certificate, as applicable, will be issued for the remaining warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide
otherwise in the applicable prospectus supplement, the warrants and any warrant agreements will be governed by and construed in accordance with the internal laws of the State of New York. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Enforceability of Rights by Holders of Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each warrant agent, if any, will act solely as our agent under the applicable warrant agreement and will not assume any obligation or
relationship of agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the
applicable warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder
of any other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable upon exercise of, its warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc573964_10"></A>LEGAL OWNERSHIP OF SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue securities in registered form or in the form of one or more global securities. We describe global securities in greater detail
below. We refer to those persons who have securities registered in their own names on the books that we or any applicable trustee, depositary or warrant agent maintain for this purpose as the &#147;holders&#148; of those securities. These persons
are the legal holders of the securities. We refer to those persons who, indirectly through others, own beneficial interests in securities that are not registered in their own names, as &#147;indirect holders&#148; of those securities. As we discuss
below, indirect holders are not legal holders, and investors in securities issued in book-entry form or in street name will be indirect holders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Book-Entry Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue
securities in book-entry form only, as we will specify in the applicable prospectus supplement. This means securities may be represented by one or more global securities registered in the name of a financial institution that holds them as depositary
on behalf of other financial institutions that participate in the depositary&#146;s book-entry system. These participating institutions, which are referred to as participants, in turn, hold beneficial interests in the securities on behalf of
themselves or their customers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only the person in whose name a security is registered is recognized as the holder of that security.
Securities issued in global form will be registered in the name of the depositary or its participants. Consequently, for securities issued in global form, we will recognize only the depositary as the holder of the securities, and we will make all
payments on the securities to the depositary. The depositary passes along the payments it receives to its participants, which in turn pass the payments along to their customers who are the beneficial owners. The depositary and its participants do so
under agreements they have made with one another or with their customers; they are not obligated to do so under the terms of the securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, investors in a book-entry security will not own securities directly. Instead, they will own beneficial interests in a global
security, through a bank, broker or other financial institution that participates in the depositary&#146;s book-entry system or holds an interest through a participant. As long as the securities are issued in global form, investors will be indirect
holders, and not holders, of the securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Street Name Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may terminate a global security or issue securities in <FONT STYLE="white-space:nowrap">non-global</FONT> form. In these cases, investors
may choose to hold their securities in their own names or in &#147;street name.&#148; Securities held by an investor in street name would be registered in the name of a bank, broker or other financial institution that the investor chooses, and the
investor would hold only a beneficial interest in those securities through an account he or she maintains at that institution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For
securities held in street name, we will recognize only the intermediary banks, brokers and other financial institutions in whose names the securities are registered as the holders of those securities, and we will make all payments on those
securities to them. These institutions pass along the payments they receive to their customers who are the beneficial owners, but only because they agree to do so in their customer agreements or because they are legally required to do so. Investors
who hold securities in street name will be indirect holders, not holders, of those securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our obligations, as well as the obligations of any applicable trustee and of any third parties employed by us or a trustee, run only to the
legal holders of the securities. We do not have obligations to investors who hold beneficial interests in global securities, in street name or by any other indirect means. This will be the case whether an investor chooses to be an indirect holder of
a security or has no choice because we are issuing the securities only in global form. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, once we make a payment or give a notice to the holder, we have no further
responsibility for the payment or notice even if that holder is required, under agreements with depositary participants or customers or by law, to pass it along to the indirect holders but does not do so. Similarly, we may want to obtain the
approval of the holders to amend an indenture, to relieve us of the consequences of a default or of our obligation to comply with a particular provision of the indenture or for other purposes. In such an event, we would seek approval only from the
holders, and not the indirect holders, of the securities. Whether and how the holders contact the indirect holders is up to the holders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special
Considerations for Indirect Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you hold securities through a bank, broker or other financial institution, either in book-entry
form or in street name, you should check with your own institution to find out: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the performance of third-party service providers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">how it handles securities payments and notices; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether it imposes fees or charges; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">how it would handle a request for the holders&#146; consent, if ever required; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether and how you can instruct it to send you securities registered in your own name so you can be a holder, if that is permitted in the future; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">how it would exercise rights under the securities if there were a default or other event triggering the need for holders to act to protect their interests; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if the securities are in book-entry form, how the depositary&#146;s rules and procedures will affect these matters. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Global Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A global security is a
security that represents one or any other number of individual securities held by a depositary. Generally, all securities represented by the same global securities will have the same terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each security issued in book-entry form will be represented by a global security that we deposit with and register in the name of a financial
institution or its nominee that we select. The financial institution that we select for this purpose is called the depositary. Unless we specify otherwise in the applicable prospectus supplement, DTC will be the depositary for all securities issued
in book-entry form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A global security may not be transferred to or registered in the name of anyone other than the depositary, its
nominee or a successor depositary, unless special termination situations arise. We describe those situations below under the section entitled &#147;Special Situations When a Global Security Will Be Terminated&#148; in this prospectus. As a result of
these arrangements, the depositary, or its nominee, will be the sole registered owner and holder of all securities represented by a global security, and investors will be permitted to own only beneficial interests in a global security. Beneficial
interests must be held by means of an account with a broker, bank or other financial institution that in turn has an account with the depositary or with another institution that does. Thus, an investor whose security is represented by a global
security will not be a holder of the security, but only an indirect holder of a beneficial interest in the global security. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the
prospectus supplement for a particular security indicates that the security will be issued in global form only, then the security will be represented by a global security at all times unless and until the global security is terminated. If
termination occurs, we may issue the securities through another book-entry clearing system or decide that the securities may no longer be held through any book-entry clearing system. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Considerations for Global Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rights of an indirect holder relating to a global security will be governed by the account rules of the investor&#146;s financial
institution and of the depositary, as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of securities and instead deal only with the depositary that holds the global security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If securities are issued only in the form of a global security, an investor should be aware of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an investor cannot cause the securities to be registered in his or her name, and cannot obtain <FONT STYLE="white-space:nowrap">non-global</FONT> certificates for his or her interest in the securities, except in the
special situations we describe below; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an investor will be an indirect holder and must look to his or her own bank or broker for payments on the securities and protection of his or her legal rights relating to the securities, as we describe above;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an investor may not be able to sell interests in the securities to some insurance companies and to other institutions that are required by law to own their securities in
<FONT STYLE="white-space:nowrap">non-book-entry</FONT> form; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an investor may not be able to pledge his or her interest in a global security in circumstances where certificates representing the securities must be delivered to the lender or other beneficiary of the pledge in order
for the pledge to be effective; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the depositary&#146;s policies, which may change from time to time, will govern payments, transfers, exchanges and other matters relating to an investor&#146;s interest in a global security; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we and any applicable trustee have no responsibility for any aspect of the depositary&#146;s actions or for its records of ownership interests in a global security, nor do we or any applicable trustee supervise the
depositary in any way; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the depositary may, and we understand that DTC will, require that those who purchase and sell interests in a global security within its book-entry system use immediately available funds, and your broker or bank may
require you to do so as well; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">financial institutions that participate in the depositary&#146;s book-entry system, and through which an investor holds its interest in a global security, may also have their own policies affecting payments, notices and
other matters relating to the securities. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There may be more than one financial intermediary in the chain of ownership for
an investor. We do not monitor and are not responsible for the actions of any of those intermediaries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Situations When a Global Security Will
Be Terminated </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a few special situations described below, the global security will terminate and interests in it will be exchanged
for physical certificates representing those interests. After that exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors must consult their own banks or brokers to find out how to have
their interests in securities transferred to their own name, so that they will be direct holders. We have described the rights of holders and street name investors above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the applicable prospectus supplement, the global security will terminate when the following special situations
occur: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for that global security and we do not appoint another institution to act as depositary within 90 days;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if we notify any applicable trustee that we wish to terminate that global security; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if an event of default has occurred with regard to securities represented by that global security and has not been cured or waived. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement may also list additional situations for terminating a global
security that would apply only to the particular series of securities covered by the applicable prospectus supplement. When a global security terminates, the depositary, and not we or any applicable trustee, is responsible for deciding the names of
the institutions that will be the initial direct holders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc573964_11"></A>SELLING SECURITYHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling securityholders are persons or entities that, directly or indirectly, have acquired or will from time to time acquire from us, our
securities. If the registration statement of which this prospectus forms a part is used by selling securityholders for the resale of any securities registered thereunder pursuant to a registration rights agreement between us and such selling
securityholders or otherwise, information about such selling securityholders, their beneficial ownership of our securities and their relationship with us will be set forth in a prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc573964_12"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We or selling securityholders may sell the securities from time to time pursuant to underwritten public offerings, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;at-the-market&#148;</FONT></FONT> offerings, negotiated transactions, block trades or a combination of these methods. We or selling securityholders may sell the securities to or
through one or more underwriters or dealers (acting as principal or agent), through agents, or directly to one or more purchasers. We or selling securityholders may distribute securities from time to time in one or more transactions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at a fixed price or prices, which may be changed; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at market prices prevailing at the time of sale; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at prices related to such prevailing market prices; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at negotiated prices. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus supplement or supplements (and any related free writing
prospectus that we may authorize to be provided to you) will describe the terms of the offering of the securities, including, to the extent applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the name or names of the underwriters, dealers or agents, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the name or names of the selling securityholders, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the purchase price of the securities or other consideration therefor, and the proceeds, if any, we will receive from the sale; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any over-allotment or other options under which underwriters may purchase additional securities from us or any selling securityholders; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any agency fees or underwriting discounts and other items constituting agents&#146; or underwriters&#146; compensation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any public offering price; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any discounts or concessions allowed or reallowed or paid to dealers; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any securities exchange or market on which the securities may be listed. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only underwriters
named in the prospectus supplement will be underwriters of the securities offered by the prospectus supplement. Dealers and agents participating in the distribution of the securities may be deemed to be underwriters, and compensation received by
them on resale of the securities may be deemed to be underwriting discounts. If such dealers or agents were deemed to be underwriters, they may be subject to statutory liabilities under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time
in one or more transactions at a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable
underwriting agreement. We or selling securityholders may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to certain conditions, the underwriters
will be obligated to purchase all of the securities offered by the prospectus supplement, other than securities covered by any over-allotment option. If a dealer is used in the sale of securities, we, a selling stockholder, or an underwriter will
sell the securities to the dealer, as principal. The dealer may then resell the securities to the public at varying prices to be determined by the dealer at the time of resale. To the extent required, we will set forth in the prospectus supplement
the name of the dealer and the terms of the transaction. Any public offering price and any discounts or concessions allowed or reallowed or paid to dealers may change from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We or selling securityholders may use underwriters, dealers or agents with whom we have a material relationship. We will describe in the
prospectus supplement, naming the underwriter, dealer or agent, the nature of any such relationship. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We or selling securityholders may sell securities directly or through agents we designate from
time to time. We will name any agent involved in the offering and sale of securities and we will describe any commissions payable to the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, the agent will act on a
best-efforts basis for the period of its appointment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may provide agents, underwriters and dealers with indemnification against civil
liabilities, including liabilities under the Securities Act, or contribution with respect to payments that the agents, underwriters or dealers may make with respect to these liabilities. Agents, underwriters and dealers, or their affiliates, may
engage in transactions with, or perform services for, us in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling securityholders may be deemed to be
underwriters under the Securities Act in connection with the securities they resell and any profits on the sales may be deemed to be underwriting discounts and commissions under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All securities we may offer, other than common stock, will be new issues of securities with no established trading market. Any underwriters
may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity of the trading markets for any securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any underwriter may engage in over-allotment, stabilizing transactions, short-covering transactions and penalty bids in accordance with
Regulation M under the Exchange Act. Over-allotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed
a specified maximum price. Syndicate-covering or other short-covering transactions involve purchases of the securities, either through exercise of the over-allotment option or in the open market after the distribution is completed, to cover short
positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions. Those activities may
cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any underwriters that are qualified market makers on The Nasdaq Global Select Market may engage in passive market making transactions in the
common stock on The Nasdaq Global Select Market in accordance with Regulation M under the Exchange Act, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the common stock. Passive market
makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if
all independent bids are lowered below the passive market maker&#146;s bid, however, the passive market maker&#146;s bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the
securities at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
compliance with guidelines of the Financial Industry Regulatory Authority, or FINRA, the maximum consideration or discount to be received by any FINRA member or independent broker dealer may not exceed 8% of the aggregate amount of the securities
offered pursuant to this prospectus and the applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc573964_13"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in the applicable prospectus supplement, the validity of the securities offered by this prospectus, and any
supplement thereto, will be passed upon for us by Cooley LLP, San Francisco, California. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc573964_14"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our
Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;for</FONT> the year ended December&nbsp;31, 2017, and the effectiveness of our internal control over financial reporting as of December&nbsp;31, 2017, as set forth in their
reports, which are incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Ernst&nbsp;&amp; Young LLP&#146;s reports, given on their authority as
experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc573964_15"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of the registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> we filed with the SEC under the
Securities Act and does not contain all the information set forth or incorporated by reference in the registration statement. Whenever a reference is made in this prospectus to any of our contracts, agreements or other documents, the reference may
not be complete and you should refer to the exhibits that are a part of the registration statement or the exhibits to the reports or other documents incorporated by reference into this prospectus for a copy of such contract, agreement or other
document. Because we are subject to the information and reporting requirements of the Exchange Act, we file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over
the Internet at the SEC&#146;s website at http://www.sec.gov. You may also read and copy any document we file at the SEC&#146;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-SEC-0330</FONT></FONT></FONT> for further information on the operation of the Public Reference Room. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc573964_16"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; information from other documents that we file with it, which means that we can
disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus. Information in this prospectus supersedes information incorporated by reference that we
filed with the SEC prior to the date of this prospectus, while information that we file later with the SEC will automatically update and supersede the information in this prospectus. We incorporate by reference into this prospectus and the
registration statement of which this prospectus is a part the information or documents listed below that we have filed with the SEC (Commission File <FONT STYLE="white-space:nowrap">No.&nbsp;000-30171):</FONT> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017, which was filed with the SEC on March&nbsp;1, 2018, as amended by Form 10-K/A, which was filed with the
SEC on April 24, 2018; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the information specifically incorporated by reference into our annual report on Form 10-K for the year ended December 31, 2017 from our revised definitive proxy statement relating to our 2018 annual meeting of
stockholders, which was filed with the SEC on April 24, 2018; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our current reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> which were filed with the SEC on January&nbsp;3, 2018, February&nbsp;22, 2018 (except for the information furnished under Item 2.02 thereof and
the accompanying exhibit 99.1), March 23, 2018 and April 17, 2018; and </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the description of our common stock in our registration statement on Form <FONT STYLE="white-space:nowrap">8-A,</FONT> which was filed with the SEC on March&nbsp;31, 2000, including all amendments and reports filed for
the purpose of updating such description. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also incorporate by reference any future filings (other than current reports
furnished under Item&nbsp;2.02 or Item&nbsp;7.01 of Form <FONT STYLE="white-space:nowrap">8-K</FONT> and exhibits filed on such form that are related to such items unless such Form <FONT STYLE="white-space:nowrap">8-K</FONT> expressly provides to
the contrary) made with the SEC pursuant to Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act until we file a post-effective amendment that indicates the termination of the offering of the securities made by this prospectus and will become
a part of this prospectus from the date that such documents are filed with the SEC. Information in such future filings updates and supplements the information provided in this prospectus. Any statements in any such future filings will automatically
be deemed to modify and supersede any information in any document we previously filed with the SEC that is incorporated or deemed to be incorporated herein by reference to the extent that statements in the later filed document modify or replace such
earlier statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will furnish without charge to each person, including any beneficial owner, to whom a prospectus is delivered,
upon written or oral request, a copy of any or all of the documents incorporated by reference, including exhibits to these documents. Any such request may be made by writing or telephoning us at the following address or phone number: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Sangamo Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">501
Canal Boulevard </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Richmond, California 94804 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(510) <FONT STYLE="white-space:nowrap">970-6000</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Investor Relations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>$200,000,000 </B></P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g570679g76n76.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PRELIMINARY
PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>April&nbsp;&nbsp;&nbsp;&nbsp;, 2018 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><I>Joint Book-Running Managers </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:16pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:16pt">
<TD VALIGN="top"><B>BofA&nbsp;Merrill&nbsp;Lynch</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>J.P.&nbsp;Morgan</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Cowen</B></TD></TR>
</TABLE> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g570679g13d40.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g570679g13d40.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1MX4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $4< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< 5H  QLE1QP!6@ #&R5'
M' (   (  !P"4  15&AO;6%S(%1U8V-I87)O;F4 .$))300E       0:7FC
M:U"JZP94JP\.6!BB"#A"24T$.@      Y0   !     !       +<')I;G1/
M=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E
M $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;654
M15A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\
M9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M
M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M
M$     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L
M      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#
M;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O
M;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,    #
M     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^            !"
M;" @9&]U8D!OX            $)R9%15;G1&(U)L=                $)L
M9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!JN3^
M"G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,
M    3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M        4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN
M9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,
M969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!2
M96-T5&]P;&]N9P      .$))30/M       0 \     !  $#P     $  3A"
M24T$)@      #@             _@   .$))300-       $    >#A"24T$
M&0      !    !XX0DE- _,       D           $ .$))32<0       *
M  $          3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8
M 0"AF9H !@       0 R     0!:    !@       0 U     0 M    !@
M     3A"24T#^       <   _____________________________P/H
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H   X0DE-! @
M     !     !   "0    D      .$))300>       $     #A"24T$&@
M   #-0    8              IT   5*          $
M         0             %2@   IT                      0
M                   0     0       &YU;&P    "    !F)O=6YD<T]B
M:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L
M;VYG          !"=&]M;&]N9P   IT     4F=H=&QO;F<   5*    !G-L
M:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)
M1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M#$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M"D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   *=     %)G:'1L;VYG   %2@    -U<FQ415A4     0
M &YU;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%
M6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%
M6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX
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M^L^]]?:CO_G,W_JAKCZ@/$3U.HQS-5NO'[O4!X((_P 6]^XG]O6:SH&&-?\
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M>]SOL[J[@:P?TUK6@.@[?I,/TO[*2&QN?^[^*A:X[#N;(TX.LS[?^DBH=_\
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M:USO^BJ_[*#:BT86,2X-+AO<!N#BZ?4]-SW;/_!%K))*<@]+XCI^+$D$&QW
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M;2R[<=HJ<"-L"/I;O=])1^R=6$1U!C@#/NH:26_N^RRO_.VJSE":SM( @\Q
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M &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %
M: !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !3DU- "H
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M   "G0         & 0,  P    $ !@   1H !0    $   $^ 1L !0    $
M  %& 2@  P    $  @   @$ !     $   %. @( !     $
M $@    !    2     $X0DE- _T       @          /_A 5!-30 J
M"  ( 1(  P    $      1H !0    $   !N 1L !0    $   !V 2@  P
M  $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @   !(   "PAVD
M!     $   #$    \    \     !   #P     %!9&]B92!0:&]T;W-H;W @
M0U,V("A7:6YD;W=S*0 R,#$X.C T.C(T(# Q.C4X.C Y %1H;VUA<R!4=6-C
M:6%R;VYE      .@ 0 #     ?__  "@ @ $     0  !4J@ P $     0
M IT         !@$#  ,    !  8   $:  4    !   !/@$;  4    !   !
M1@$H  ,    !  (   (!  0    !   !3@("  0    !              /
M     0   \     !_^% &FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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MJVY1X,C>_-)5=#M8JSZH^8$48E,L?(J&>' J8I1LB<HF+'O#(T]Y=@2K*(.
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M.O&N=&RNT8!M@T\<;?6%?K)X]NM!\EGY13<1^8XSP'=W4>1[^\?P#X;]0Z>
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MOF5IRYW-B.K+4^]9^44WW^8WSQOW]*-(=-^_O#KN/7PZ[  ;B.SPRV5X=_\
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M_DT:VJW2F:7)V%\K+2KM.-B14F9EB>O0JY$F3-)\DHCYA=PB9!QNGNCO W7
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M_"VSNT)Y7XC#.K7L!ZJY!Y0SAZ$>8,M,^3G'_)+?-P+\$0*)O2NP&V _PA*
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M34IV2V_9VO\ </[EY#OY]P'ZK/!/X AXF^'T#X&E-?4?OH#2V^,[7^\.ZKR
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M A^A0+T^%L&X!W;FUZX=KME-?X2[/VZN_6'C0#4W,G51/(:\>I-OE4=%72>
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M :?ZG[0ZZ6OE.'V-KV&NB@-=*@,#9RVV]Q7+(;!L&V.;=RB(@( (_G/N E$
MZ@!MMBCW;:GPLV5Y;4;/<M3C6'7TY7[IL1J=#;CIK>J?8LZ3M?\ DVV^X6'\
M#L?M<@IN?M=<$!(X VL-+<9]P7.8B !A?*_,(]_N<W /_P#8?1  '*.PEVZC
MN/B'2!M=LI\)MG\HTL<:PZYN>(O())/.^@\YH>BKI//_ -F^W@4JQOX(;0VX
M:@D8>,H&EK&Y%]=!4#@3.>Q@+AG+0;=PFQW;QYB]!Z",./*/>'*7N_A'4#:W
M94$7VFV>L;:#&<. !OU=TCL-U#@#V #T5=*%E!/1SM]<#W2MD-H/&! /%6'$
M<B+)MQTMJ3/N"YS#;?#&6>[81]SNX>P #8H0P@(>([B.W@;<=]3X6[*?";9W
MWUAC.&C7B;GND>8BWDL"*>Q7TH#_ .SC;VWN;G9#:$FP%M$C#5:<R"3R\:MC
M.*/#F7IK)$0]A<6Y&EVJ>*\0L#NHVCV:0;$?1^/*XTD&9UFD6JF5TS=(K-'B
M G!5LNFJ@L4BI#$#B]@MI-G8V"2&I6/X+&<5M!M$\&W\5@,K++N,3'&70AR0
M@E#B%)<:4!9:2E:"4D&O8.G#H[Z0,2VQ@2L,V'VPQ!A&PVP,13T+9C&YC"9,
M793"6)<=;D>$XE+\=YMQB2UG"V7$.-N!*PI-:Z>X+G/;?W&,L<W00#W.[@(;
M[[#O^= \P"&P"&W*(!OU'J/9^%NR@('A-L^4\/NQA@L+?]8 &MSIS-NH5Y![
M%?2@05>QQMX%<0/!#:*V8&Q_H_6X/,6RBYUUJ/<$SD4Q1'#&6#=Y1 ,<V_83
M"(AN(^B!$ #EWYN[;8.@B ZGPMV5(/\ ";9X6L=<;P[@!?3[(XZD =?.W![%
M72<E0)Z-]O2-0;;'[07S$VN?M?>V@NJ]LMAQL:XC@;.7+L&%LL]W0?<YN&X"
M!@'J P_7FY?A;<HCW;]0WGPLV5O<[4;/:G4#&L-UNFWX0;<>JUN/ BJ?8LZ3
MK91T;;?'AXW@=M#<',#<WP_4FQN;B_+B*Y#@;.0#M[BV6.O3<,=7#H.^P?")
M$"&VW4?@B/7OZ"(QX6;*'7PGV=_3.':\>1D#76W(=6EJJ/1;TH7RGHWV]_Z7
M@?M" D@VT*<./+4Z$ZV-K$UZ,^3+QKD>FYRMTE<,?7:IQJV)IIBA(66IST"R
M6?+7"D.$V2+N4CVK=5THW:.'!6Z:HK&2075!,Q$CF)XQTX8Y@N)[+X<SAN+X
M7B#Z=H(SRVH.(1);J6DX=BB"XIN.\M:6TK<0G.I(2"M*;@J /UU]1GL9MCLY
MTEX_,VAV3VEP&&[L+B,5J7C. XKA<9R4YM!LVZF,W(G166G'UM,/.AE*RX4-
M.N!)0A2A[C:^6J_2VFE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4K5[B-P
M//9K?8X6A[&WK[6HRZZ\X4SN9CWDI"R$[3GLM&,WL*=)T@$C#U^4BG("X1(N
ME) BH86YUPUEQ9"6 [F1F*TV3HDA*@E8!(5IH5 C3E6.^R72V0K*$$YA<C,"
M4DBXUU"2#Y:U#D>!+-1'R,S!93K06**2L<96)V:EL@+O*]773C KBOP23E@Y
M:3+F-1+B269RK9M.Q3@Z,PU<-I$79W:B>8,09ME4TK*2E2TI2W92@) 4;*!%
M[O)(NDC0@CA6,8;M[I<2"G,$$ESQ4DLE*=""0-VH'4$W!O<FJ]1>"K,<+B?B
MFI-LR+6Y^;SEA.YXKI':7\G(1=-&R1V0@8LI!ZWJ5;*->CY:\JKF"&J[94R7
M;7(1QW:Y@5I<G,J>B+0VL)8?;><T +F4MW(&=7C%+?-?5K:I3$=#4E"EI)>:
M6VBY)"<P78$A"1E!6>".'*]?.Z<(/$-<;>C=XZZXYQPYGLOUK)-MK-)F+4$4
MP:U-#!T*@@PDW=10):)2T5;&-JA[/(+5NDR@,[5$0[&=&#B+ SMQN;';1D*'
M7<K*FD+6$W)69"B2D+\0)6Z@I&9P70I13F*<A<5Y:\X4VV2X'%)05 #+N1QR
M>,5H:4E7BH("PD**0K-SX=.#;..&;Q19*;N]/DZ%2,60&,R4VMVFZP["6-!&
MPDG$V1PV/7.V(/:][G-RE&D0I8'U;EEKFM#A$5UM)6R3GTF:P^VX$H6'''5.
MYU(;)&;NBZ 0JUE;U )"0H9+W40@),176EH*E(*$-I;RI4L7*=R KAH1D60,
MV4Y[62"HF_+]PT97N6:IW* QF%Q8UJ:A)C$D>:3GXU.00)-X_FKJSRC$L: N
M$E.W1Y2XQWZY>L%D"M^I% 8PU43^B>1E;;<IE#"6;OW6DAXV2H@Y7$MEI1<&
M5+8<4,F5.?>.%2_<!-:V'5/%RS5DD%H74.:"O>)#>JEE .;,K+D0$I'C$VA+
M<!DHWHT/7:Y,U5269XKX4*+9I(B\[1I6^2_#=)3ZQY-Y<ZVRE;'5O2#)]!IP
MLI&I2LHR;0ZT$LF6.D%G(5C$ 7%+4%V+LQ:$^*M+:9039.11"5V(5F!L"2%:
MD6J@PR$!*2F^[C)4;J05E@G7,D%2;Z6(N1JG@:WPQ%3'V.<4XTQ])R368D:-
M0:A3WTLQ8EC&4F[K<!'P[A^TCB"8K%L[59F70:%$0;IG*EO\'6O>6'7G7$IR
MAQQ:PDFY 4HJL3SM?C68T@MM-MDYBA"4$@6OE %[<N'"LAZMU<II2FE*:4II
M2M%+OY0/#E#CK,\EH&^N'55REEO%C^)91D*+]5YANF6&Z66U-A<S[9H-/?(5
MY2#AI19RBX7L3YK&O&3($GRS-;S?O];U3F'Q_JO?R>CMJ&O'SC9PBQ,--MH+
M.[?(4Y0R%FPZ]A0DH^ HEE,A%6YKE!2HVB9>QN08D(RFUB<EKQ(/(RRM&];,
MK"+ I-N7#RZ>O73-H3\A!T]-O-QK8MYFJLL<ML,-JL)HUDD48Q9%\1!F,.4L
MK7[U8T 46,^*\ 2,J!+I*\K(P Y<L"E$R:BZC>+<_7E\]3<7MZ\"?U5A^0XT
M,=,;-&5TM:M[A.8@Y6R1DN9Q2(Q&7A(U[;6:<K7(6;N,9:[;'.25!Q(.'M5@
M)E"#BYB ?6 T6B^7%G-NT:<>/ZAYODJG..VIH?&CC*_8GOF6XN-E@A\?N8AC
M)Q[*>QW95)![/Q4#*Q+2,L-2NT[2P5,2R1C67]*66,+6'':3V4T4R;*.]+'T
M^;Y>%2% W(UMU:WOPM58@N+.F6=!IZNT[($P^=TS(UM3:LX^ %@9UBS(:6+[
MC5D+4K8TJ<^FXVV"Y(NZC[ ZKK2(:&FY"<9Q[I@J[6[1\?5>_#_'E>@5V>O#
M0\_+PZR*OS#V>:;FIDU>5AO*LC/:;6;XT0E2QINU5RU2=GA&#QF\B)&5C7I$
MIFG3[)95F]<-U$D6,DT7<QDM'.W$$6J0H'Y?-PK-FE332E-*4TI32E-*4TI3
M2E-*4TI32E?!TY19-7+QR<$V[1!9RNH/<1%!,RJIQ^0I"&-^+52$*<6AM NM
MQ24('6I1"4CSD@5;>=;8:=?=4$-,MK=<4>"6VTE:U'L"03YJU5>UZMW>486+
M+<#,++S-;+-5X8A[+1R,-%N$57QJX8M7%A+2+YDR[,>2>OW\BW/*N%46[2*:
M+1I'O=-3)N&,NP\ E1TIC3#'EA]IA]4A]!#7=@,X.QV6W',X9;9::4&$)4MQ
M]Q#Q;\??PG"MHI47$]M,.G..S\+3/PP0I,Z&B!$=0M\X61A!BS94AEC=*EO2
M9,MHS7%H98AL+BI?O?&"RM85A:VVCU8^E6-O-N*<U>*-UW\2XB%TEC,5'R"*
M)I1G.Q:ZLPQ=.Q>/$%XZ4*:9FH]Y%.RZW&TIG)D35O)>Q*(N,G$5MA26GT/I
M4G>I;4M88=BOI3'=0WNVU)>9/<\9YM]L[_9-2L'<@82S'7'P#$VI[F!LOJ;<
MD0G82T.&,J0VVVJ6QB$-QR='=?+\AMR+,O.GQGH;R?)7-G&1EGAWXK.*VHT-
MG4',5*Y,QW8')K!$/G[L'SCAFP-'G*BJUEV!"MP0CT# F9(Q^?G$IS<P%+ZE
MT9=&6SVV&SKN*XH]B3<EO$Y,,"'(9:;W33$5Q)*'(KQ*\SR[D+ L!< "Y^8?
MJC?JCMO.B?;V)LSLS$V<D8>_LWAV++5BT";)DB5*G8I&=2EV/B<- :"(;)2D
MM%68JLI15E398^5'XD-Q (O&8[  B(UN6V+T =QVLPAU =]@-N'0=N7<0]&]
M@?8O3[*QS7A:9&U[#>""/1PYDV!\ /U;G2\"1WMV)L!J3A&)^+[GC;',O G^
M<=?ZMR)'RHO$@ "/HW&.P#]K4QT#?Z;K9@#N =@$V_01V'4#H(V+X&3CU^R;
M%TXFQ^P">K6WZS4GZMOI? *N]VP]@?Q/BO#K'V] MQT*@=#QT%1[Z/Q'[;A&
MXT'O_<S+CL.X[;[68/@\O*(CT#J/4-/8&V-_"<<Y#6=&%^O^CSK?@.H7UJ/;
MO=+NI.';%<^&#8F;:Z7^W_"VJB; 7U*;5/OH_$?\+\Z\9[E';I6I<0\0W#Z)
MAW#FV_$("'3?4^P/L9H>Z<<L1?69&!/,"_<%KV%M!QTXU/MW.E[QAWMV)N--
M,'Q,CJO;OZ3:Y!XWUTN-2#RHW$@)>;T9C(-RB(<U;E@VVZ[C]$W7<.H;;;]P
M?(]@?8N]NZ<=-C8D3(VOF[@L.TGEK4>W<Z7B+][MB!F22 <(Q/Q=-+_;[6_$
M<.8MU3[Z-Q']_HO&>VPAMZM2_P!.   A]4NX==Q#OW#Y=1[ ^QEOXSCE[WOW
M;%]S^8VOP''15P>%5>W<Z7N(PW8FVHMWHQ3W0M?^G+\;VTU%J!Y47B0-N(1F
M,MO8-9F2CW (?NE'J.Q@V]O3??0] ^Q8(!E8Z+Z7[NB$7OP_B/:/,.&NA/U;
M?2^H$C#MAR!R[S8L#:UQ;[>GC8Z'@=+FH]]'XCP[XS&/?WC7);H41Z;@%EZB
M  (]._8P[;=SV!]C-/LG'03_ ,\C6N.(N8(YFW VTUXWCV[G2\/Z.V((N/Z)
MQ,62>!([^'6PO87OK8=0WE2.(\!Z16-#!L&_+6Y@#!MU./*:Q]=@'H&_7K^*
M1T#;&D'[*QP$=<V*>(TX0N9[./*Q%X/U;O2Z"+8;L4H6UM@^* @C56AQOD.W
MYQ?M)\I#G^P1N0W;^/QT52KT):S1HMZ_*ID-()VNIPA2.@-85/.M^R3;T13(
M*1O/%0."O(0Q3Z?%>A;9*$_@S;+^-%.(8NB ^%S(I4&58?B$J[?V&,KF\BM
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M&3W7>Z\<V?@8I+2E3>+LI#(D27$QTE)4VV$I6XX05UACWT?B0YA_.S&7+_\
M9F8$?X LX .VPCN @ [@'3<!#ICT#[&6'V1CM^%N[8H%^(L3 X&]K6)%KZ\#
MYQ[=WI>N?M=L1;E]IL5)[188[K:Q.8$)-[#C< \J/Q(&[HW&703 /T-2_3;Q
MW]9P  W PB(AL!?$=M]#T#;&?A&._P TC[-BZ@\K" 2>('7STO:@^K=Z7B/N
M?L1<9@?M/B=A;@;]_P 6X%6HME\A- \J/Q(;[&C<9;]1Z5F8[@W$0 /67<3
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MQ&29'=(QK#P X)Y;W1CJR[LJWB@O*GXAY(U^&^V>FG4!W_0W6ZB( &_U<>P
M_P"S8>NNV]L.USV27Q%OMTG@.']%'T^7LKQSVA$C6W2DSJ#?^!SFI*0F]_">
M_+AU:7J \D:_*  &>6?3_P!&R_?L( (?1UTV >@!TZ?AT/U0[1_U27;D._:.
ML'7[4Z\->OT6)^H(DI 'LI,:#CX'.=1%[>%!MQX<-.'&X/)&O@  ]WAGL&W^
M39QW &P!]70[>T?;W>S0_5#M'CLFZ>.G?M%KGG]R>0X<-=>R@^H(D  #I18%
MK:^!SM]!;3^%&E^?'YGO1LAX9Z9_+^AJM[-M_JY[^GX/$/9H?JAV3QV2<//[
MN)[?]E=O*W+SQ[0B3RZ4F!VC8USJM?\ E1QMP\^FM3[T=(;_ +/3,0ZCL.-E
MQZCM[;R/LZ_P!L  &H/U0S)M_!)S3JQM OK?\4_N[.-5>T)D_P#[4F>-]=CG
M#KIP)VG/5Y>H@"U0/DCI'82AGIF #L/[&JW40$1'<?7GY>GL\0-XA]4,SSV2
M</EQM/5;\5>NG50_4%2K$#I28 -C_(UPZW))_E0.-SIZ;U(>2.D W_1Z9]1
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M-76XAT\-SG<*<&S#C0PW$T8B4G& LOY84V)NK][$Y+]U[S/9=MWER>-F3T>
M_43R,%C;41U=([,D[1[-O;/A8V36R(>]Q?!\4[JR^$3I? &%;C<YVKE\.;T;
MO(NSR^2-D"_Y>F8CN80_0V7VYC#W[>O0CMMT$ $-Q$1W 1ULE?5#,JN/!)RQ
MM>V.)X#E]RO46%JYQ/U!,E-C[*3!(N?Y&N6N>)MX4'XB-23>YH/DC7X[_H\L
MP'IL(8V6Z!OOL/T<]?9W@(;^W;8/JAVQ_JFYR_IM/$#_ +*/9IV6-];C]01(
M-_\ E19OR_@<YH+Z_P"LX.O#CIRM4E\D=(%']GEGMU';W-E^\1WZ_1UW;B([
M=!W'OT/U0S1%CLDY?37OV@:#L&$\>&O4//4CZ@F2#?V4F.9MX&N6N3?X4<+W
MTXZ\>%<?>C'X=V>F@#R@7?W-EQW -N_Z.NHCU'V (]VW09]L0USV2<.M_NVG
MK_[*TZK\>VYN*?:#R1:W2DR+ #^1KATTZ]I[=9X6!.@Y&?>C9#;8<],Q*/>'
MN;+?3=YA#Z.=PW-UV'?81'KOUU'MAFO@DY?D>_:>'  _:JV@YZ7ZJGVA,FUC
MTI,$=7@:OB3<D?PGTUN0-;=9J?>CG_AGAEXB/Z&JW>/X+R'XPZ[CU'3VP[7/
M9-T\ONVCY>])ZA;JJ1]03)'_ -J+'/\ U-<XZVX;4#KUZS<\ZXCY(Q^(F_1Y
M9@ [[ &-5PY=_$!&]#U[A[@ZAOJ1]4.UI_!)PVMQQM/#J^Y/5<=8N=:I/U \
MDWMTI, &]@-C7!EO?4'PHO?4'EP]'+WHZ0\,],P_>C[FSC<.[??Z.^40'V<H
M=_B( .J1]4*R#_))P]8[]HUTMI]J=/+KZ-*J]H5*M8=*4< >Y_@:[<>7^%-C
MSTL!8]>M0'DC9'EY?=[9[=0_8T5Z@(AN _1R/?L "(;=-PVVVVJ]L.S<'P2<
MN.O' ==;'[E \^'"]C5(^H(DY<OLIL6[-C%C32X-]J#QMQ'DM:I]Z.D-M@SR
MR[NF^-EQV$.[OO7</>8/$?DW#4>V&9^"3GFQM',&_P#1/;H>0T[:GVA,GETI
M,#JOL:X;>2^U'#F1UVM87!REEWR:SW*-J961/,;6$*TI])JO8CT-60$YJA6(
MNNF?E7"W,P(#\T=VL&_FC"V*J"'GUQ)YXW/[.=-;6 0'(2MFURRO$L3Q#>=]
MDL@#$9S\P-%!PUV^Y#V[*\PWA&;(D')7<;?_ %'4C;?'8^,HZ0F<,2QL_LY@
M?<RMEUS,QP#!H6$F4'1M!&R]U]QA_<E"MR%[K>NE.\5BWWHU\(B(YX9_)^AL
MKN ]P=?7C?H'P>FP\H &_370>V':M;P3<XW/V\'[*XWUOU\JXCVA,B]_908[
M/X&KN#R-_"?D !RT UTH'DCI#??W>FG?N(!C=<.\-A#K>1'J&V_X^G4=#]4.
MU8CP3<U%M<;1YN&$CAKZBH'U!,D&_LI,<;Z;&N<^/':@\>!MPY<3=[T:_P";
MG'/+,1W'?]#98.FX#MTO/?N'41W$0_!OI[8=JUO!-RUK?=M/G.N%<^-A:QOQ
MO:GM").;-[*3!-]3X&KO;JTVG'I(4;:=M2/DCGXCN.>6>_@(8W7#;<>O0;R(
M;;>&W?X[=-1[89H  ;)N<;_=M.OHPH&]];W^/6I]H3)))/2BP38V_@:YI>W7
MM.1:V@%M+Z::5L_PF\#3OADR'.7I?)J%S3F*6^J18M*HJ0 MC/)NOS /Q>'L
MDP"I4P@S-^S V3$PN@5\^'FO-J<-T@]*;>W.#Q,*1@2L+5&Q-O$3(.(B7O,D
M67'+6[$*-ES&2%Y\ZK9,N7QKCVKH)^IF?Z&-K,3VG<VT;VC3B&SLG 4P4X K
M"BR7\2PK$!*[H.,X@%A PTM;G<(*B\%[T;O(OT'UX_7U=32E-*4TI32E-*4T
MI32E-*4TI32E-*4TI32E8WRKB>DYHJ+JCY CG$I7'BP.%VC61?1:IE0:NV8&
M!W'KMW)0\P]<%V*H ;F VW,4HA<:>6RO.V;*X7(!Y@\#Y!5MUI#R<BP2F]]"
M1J.T:UB&T\&V!KA+62<F:],C)VR2BI2=<L[786(NW,13;EC]L0J;=^1)!NK4
MK_:HEXW1(1-R22!PH':FK19&^B;(0$I2I-D A-T)/NEH<)N1>^=M!!Y6TXFK
M2HC*E%1"KJ()LHBY"5H'/WJU CG?KUJ<2<&V!<(W"1O>/JW+1UEE(F6@WCU]
M9IV6*I%S+F/=/4#(2#U=)58RD6R#T@N5624\T91R\<+K+K*GILA] ;<6"D$*
M "$C5-[:@=I-AI?E4MQ66E%:$D*(4"2HG15K\3QT&O'MJQG_ )/;AMF:8PH=
MAB;O9H&)B:[6X8+'D6W3#V%J54@[#7(.HQ+IW)'%A7F45:IM,K1 A5SO'#:6
M,Z&6BXIZQK&(RDK+B5(0HJ4M61M"0I:U)4I:@!JHE"=3RN."E T&%'4G(0L@
M)2D7<6;)2E20D:Z)LHZ#G8\0"*NTX$.'F/NT#D2/B+:RMM66DW=8E$+S9>>O
M/9=2_+O'L.FJ^538KF>9/O$@!42@W,_FBN5D%5(N&&/@XA)*%-DH*%V"QNT^
M,!N[!6FHLTV.NR;7L3>1#82L+ 6%IO8YU$@J*R3J>-W%GRF_56><A8@I&45Z
MXM<FTR^3K+D7#5BRLUBAHJ33&4@9LT?98J'DV4=9XL\O5X"0-'3K9\U\['%3
M!,&SM^@[QVGG&<V0I&8:DH2HC12;I*@2A5E*%TD'7L%KSC2',N<$Y3< *4 =
M0;* ("A=()"KWMU$WQK4>$G#E$GIRP5-O=HAU-8^EL6H,D\DWIS$52C2QH@Y
MH/'T6^GG33'B+#T'&$BU*62#69(,(UN0YF\+!I1EU<Q]Q*4K*% .)>)W38*W
M$YO&=4$@NDYE7WF:Y*CQ4J]M,9I"E*2% J;+?NUV2@VT0DFR+6%LH%K < +1
M4N$?"M,2HB,5%V=PACDL4C66\O>K=*M095V52L%4C9AF[ESM+!&TVQI!9*BR
MFD'R-=L"BTO&%0?+*K&+F/K+A)2"[FSE+:$FZAE600D92M!R+RVS)\4W%$QF
MDY  H[NV6ZU'W)S)!ULH(5XR0;A*M1K5?^9HP_ZRP]K+7Y!.4AII:PE31LUD
M1BI27'(5ERM&N[!"I2A(N?&N9#N%DM=83E6CI*ORLFJI&D0(F@FE3W4_E4C,
M"%)RZH22!NT,D)5:Z<S2$(78C,$B^M3W.SF"LNH.;W2K$AQ3H)%[&SBU*%[V
M)TK/6L>K]-*4TI32E-*5YQ3^<<_XYA<JY,L"03=;3RU=<=XV@' 02S$C6(R%
M8X*+=O(1I2J-)1F\-72-6$I9LT.8F>>R+<Z)T9.1AH5S)MP\FNO5Y>OLJ@E0
MU/"_/RGD .0YFWITM3%W&+G?(,G4X5C2JB+[(E@ R996-N*:V(HA\UC9B.C+
M\FU8QK:2<2[%_(-JLZ9.6!G!:Q*.)!5TN=RA&"!KY=-1K\=_BJ$J)ZOC_P .
M%[>M\@R?$E=K7AR@Y&>OSX!BK)FZ,Q]8YX[2'DG]:AH>N349?1?C<X.5@F78
MLNU^>JD?*+1BS=]#L(U^V4(M+D$D@<?)I^KY?\:FYL#P!('FMKQ[>SXJQ;#<
M9^=*\%:;6'&SFZED[,I!I.$(=Q!6.VPX$K"=5G*]5Q3C%VKNZ1$Z%LD6K5.T
M.X!3=%Q7(BK)S=@J*VG&VE^?61\OKI>H"C>W&_#A^[B.9\M=9CY03*RK&B*N
ML+-0D+/:(B'<,$E%U4G$;/RM(A.W-G\1-V%-F:GR=LD&]I;0J5]GVY:ZHI/5
M:DC(J)Q3+ZW\_#TVX#3B;TSGJOKU'L\O,]ODJ]\2\:V5,@Y"Q?2Y'#96$?;#
M*HSUF2<L$8IPH,G<FCIQ45RVR63F6U39UR'=6)6O#=8XPV-!%_,55\V-'JLN
ME[]O;Y^0[-=:D*)Y>CUY<_6_6N/$5EYM?*J+*R#&UV2R9;*LI3H2JL7EDDF]
M?SH[Q<G'11)ZM.F%R72K<"M8+%%0EWJ-MJ99PUJ[):JZ1A#-HMZ]6@/ =NES
MIY^ J(/9V<];6UXV[+<>K6K\9WS/-7Q9G.56G+ID.TQ5LS!7*78)>J8TC(*B
M1>/?2?H.P33*&C:A(3!9U J0(K-8BTM5Y-JU,LRBXA1\NJYCS<->5+D ZD\>
MK2WFY^3T<:U[+Q7YJ?H-6L/=%&]J1B[U-KUBR5*CBZ7Q9'6"_0E8R B> [66
MZY%D(]C#6]K#X\,MCQ&J5&Q2\B+MO9JB,M-A:_;;UYV\X-1F)Y\>&E_/IK\7
M'LK<#AXRQ>KG8WE?M,@6QQ1ZU:9RNV/T0SB74E!U_->1*+4K8^2CVC%D=MDV
MCQ5;L<.JR9M(QZI%3<I#()14@U;-HY>O5KZ/CO5223Y+<>O4C]5;>:BJJ:4I
MI2FE*:4II2FE*:4KI23ST='/Y 4CK Q9.GGF4_IU>S(*+^:)_IJ<G(7Y1#5Q
MEO?/--9@G>N-MYCP3G4$YCV"]SV58E/B+%DR2E2Q'8>?*$"ZEAIM3F5(YJ5E
ML!S)%:UUB.7D 4?NY]@UL4HUAI22E$P1)*3BCR'BI]\4)99P1RC 19Y=*'@H
M-GYF-:H*-5GJ;T[ASOV4YY+1#3<9Y4-AR0PPPHJ+$9+<A^*W>.E!0J4\&%29
M4EW,\XH+2VIH(17E^#1%R4JDOXC':Q.8S ES)B,@EX@M^%#Q)\)FK<#J,-AF
M<B#AT%DHBLM*97(3(4XY>OTA8T-<448YRR<0]F>3D>Z3BVJ;%B_D&$-#62.M
M98]N<S%D^=M7LG&3:[!-!"75-"O%$4ER&*;$Q)/=&'*4\AU,B$B,ZA3ZU.NM
M-.R)$-Z"75_7%MMN-L/14.E2HZ1);2I2"",_ UG#\>;;C.L+@XL]B$9Y$1I#
M$>1*CP(&*Q<9$9H[AA]YE^7$Q!V.E#<U9P]]:$. YO!GC$R%?JGQF<4+"JWB
MX5E@M=,;.UV->LTQ"M%W2G#GA!(7"K:/>M43N#)H)I&7.4QQ3(F3F$I0*7Z%
MZ$L%P;$-CY#\_"<-FOC')K:7ID"-)<#:8D%01O'6EK*05**4!0 *B18FX^!O
MJQ]L-KL!Z5X$+ MJ=H\&A*V+P=]</"<;Q'#HZY#F*XVA3Q8BR66B\M+3:%NJ
M25J2E"22$@#7WW:LR@)0'+63!$# (AZ^6OIN(>/I01'8/8'?N.X=0U[!X+[-
M$&VSN!^4X3A^MK\MP+7-N)&G*QO7RE[)?2," =OMM3K>WA5CUA>PX]W*)L.-
MAQ-[@@B@9KS)L(^ZYDW<O<4;W:1'8W7X0^E0W$H;]?#< , ] "#LQLU\'<"U
MZL)P_EII>/PY6YD7%/9+Z1K$^R!ML+< =J<<O8B]C>>+E(''B,UBGJCW;,Q[
M[>ZWDP0^2^VK?F#P#\]-]N\!-T#<2@(%'NGP6V;(N-G<#!UXX3 X=?\ D/)9
M-KBQL57J/9,Z10JWL@;;$=FU6.^Z%K"_=Q[05<-1<)RU/NUYCWV'+.3?:'T>
MVKKL80'J$L&^P]-@Z"'>(_%CP6V;L;;/8$2-/N1A][V!U!C::<3;0\->,^R7
MTBWUV^VV MF_E5CW61H1B O8Z <+<2>4%S5F0 _9;R<(;[<IK[:2CN)NH@;T
MML(#]*&Y@Z"!@\=W@QLS>QV=P-/._>B"4\S8CN>X//W.I&NE4CI*Z1@/Y?[;
M&YME.U>.)5J;7"N[R".7NM-%#K+W;,R /PLM9, !$0#>_6KX(;G 3"'I/<>7
M8"C[-A'\$G9;9KEL]@=^.N$8?8FR;6/<YL#>XX<;:CC/LF=(HMFV^VU )(_E
M7CWBI!5=1^SA<BUCY"=+:!S3F7<#>ZUD\.@"'T>VKE'F !$/UV\.G@(=>@[C
MN ;,;-<#L[@)(T^Y$"^A/_-S<GGSTN!4'I*Z1C8^'VVX&A%MJL<-R0#^'Z@:
M6TMKQN;T'->90 V^6\F  ;=U\M6X .VW0TL [B&XB(B =_PM@YA@;,;-:6V=
MP,ZG^B(%M+@\(_ :<!?4'+?2I/27TC *)Z0-MA8 6&U6.DV-B-#.YZFY(']:
MPS&?=JS+T <M9,+L)NGK[:^80#;E'K+;CX@(;>&XCXZGP8V:XC9[ C:POWGP
M_+<\=>Y[>0^@ \!Z2ND;1/A]MLG4^+X68[F-N!UQ"YTS"W"XN;C4Y5QME[++
MJ%S"JYRED-RHRQ4Z>L3N+K95Q:/"WRA-@=M15DQ%NX!NX<(%62\VKYIPNES
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M42E.LL<ZJABF.H<QQ,(V*^>GG5ONNON$%QYQ;KA"0D%;BBM1"4@)2"HFR4@
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MFV_:FVW?OY]+;;V_3:4J>UM.[M3??N_3D^_NV^FTI4=L:=_:FVW0?T]+N'J
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MZE[@V#8/#8-N[2E3ZH5+O]5Z[N.XB/H2-Z\V_-^UOC;CO[=QWU%AU"E I]2
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MU?:_1'T2[+;<;+OXSC+N+(EMXO+@I3!EL,,[EB-"=02AR(^HN%4A>96>Q 2
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M9#SB#<>(2&SG:07%@E"0H_6PHDV6@*&1(4L-#*7,ZEE(+2%:&RP"L97%!"2
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MFF;F:N2DDWCJO(NKC)7'(5B*%-K3D6%J#Z<Z2D62Z'@$D"V8#>('!)"6P+K
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MB',I&+N2AA^Q,I)9G.&(E)24 C"$L+-Q)OXDN M#3[F\0H,&QL%66/K()25
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M#])3YW5SW]\%B'_J:Y_]PTWX]Z:>V9V>^#>,_G$'_CI\[JY[^^"Q#_U-<_\
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M![Y*G!2L'(P+"WY(CFAL?X]JU>(E+,?,UBY4%YCEP?*S!NV8LB&N%P98=Q7
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M'@2V(J7$NKFE"56]9$52+HI+IB!DUDDU2&#FV$BA .40YBE-L(" _"*4WM*
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M4J_Q-_SBEO\ 1Y_W1^(<W)^]W+OS;#NI4"A=>NTG5NXVPC!2P]?A\FX>L0=
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M=/"3J_Q^^"EN_<O)T]8O .;G#?X0B782;#NIZ^NM/,73[)U?O#;\XI7Z7D4
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M\[&8Z3OX1%6BUZ8-1D>U',K5R1S;(KB_(R[9>17Q\2K^9GE5M+^ORW^+]XJ
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M=<_$0\ZRW(CK??W61*4K/YP8%#VNV9VEV>V9QS"Y6!P-BHNT&-8T2@K5M"U
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M%*J3YE'AO1YTQ%T '**J:B6Y-P%1,Y-^8I@!2MF?7:F=_K=6.X1_7^*[@\V
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MI2GKM3/MNK'QO\?Q7Q#F3/\ MOXJA#IF_>G*8@[&*( I0+M3!$ "W5@1$2@
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M4S G\C+3^'QO7>(B/B'4=/8=V6_"<9Z_XS&TZO\ 0O)U\>)J.]['6O7^L/\
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M#IL:!_DXY^E4_L_K]>=2<1'WG_WA_P .NFGK:GSO9/;?X5<0&V^WZ#;SY/\
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MP.0I4BB0A@2+YT%3&.8V=W8BUC"AGR(<!MI_Z7GKJ;D7\7+85RG<ZN4A\?\
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MD6(HF<VY!(54WKK1UKJ<M,OX"-S,1]-Q4E'Q3Z(0D: =\E)2<#'VB.CP;A7
M666?5V5CIIN1OYPZL<[1<IF\V;<%//V>>KT]!2FVWKG91Z;;]EI^^_3X72J
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M!_3C'T7KU]3WRSAD^Z3ESQ'Z@JWXEY=OJ=\!'F#QY@ZB)-RC'MH.BG\+QO\
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M8.^J_% P)E_T"%$W,<3G,I3T'*=/HRLG02CMV6H=0*"8"4?H5WV.)#&-L("
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MM],>9*9=+*UM.(0\$9%*;6D$E"JUR^9MXB.[W!LR]=O\F-V\-^NWH3?KOO\
MS>'3YW'1STA<]@MLO]V,;UZO]! TM:W WOI7TS[*71GQ/2)L-I?_ %LP&^MC
M^,/-VVJ X;>(?O' ^9?D_0QNO7K_ /4>VP:GV.>D.]O /;&W_JQC>EK@?Z$#
M>UNNW'LH>E+HSN![(>PW:?"S >!\F(<;_/4_,W<1 ;_H#YE$/$!QA=?P!_B0
M1 0W_P#B/34'HXZ0O@)MEKU;,8WSX_Z%J#:_9V\*CV4>C.W_ .L/8<'K&U>
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MZB9J\5<)(68A%6SULY<(.H\P#'N$!<)+M#$5 JLYU7!N>KU];U&1(X"K8O\
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M57K=CF@WVQ05NNF"4+/9JQV<8*:F6=$>R,>#*0+*LDDEUK,(J),Y1NC*,D'
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M/:CYQ CI,ZC4Q_HHY=G'FEB)[&'X2*@GY"<ASJ5V_3TOU^@JQ_%_;M0Z\PJ
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M#-@XG(M!XNDF<C55XU(X%(SQF#A2N]Z>E]M_4FR;[%';MM/WZ@(B'U4[;E$
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M^)][7^7D?2T^9SQ)]A+!^43)'];M.^L[[XU^:1/H*=[XGWM?Y>1]+5JV_$^
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M*0<'/) HTNG8B0E1;7B4-#J9#K)2IN0$!#6*HP<O%\MAD!4IUHA!4%[I2ED
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MX<*)-&R0+.G*JKETMSN'*JJZJBAM;*DOS9,B7)679$EYQ]YPV!6ZZLK6JPL
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M^9'Q3&S'<2]'9VDVAQ_:.(PZA69MUJ#C6)3H0=:5933I8+C:@%(6D@&LP@
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I-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*5__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g570679g76n76.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g570679g76n76.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1AF4&AO=&]S:&]P(#,N,  X0DE-! 0
M     "T< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  15&AO;6%S(%1U8V-I
M87)O;F4 .$))300E       0EBZ:3T?E;;?N<!4L7_G4YCA"24T$.@     !
M 0   !     !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0
M  !);G1E96YU;0    !);G1E     $-L<FT    /<')I;G13:7AT965N0FET
M8F]O;      +<')I;G1E<DYA;65415A4    #P!( %  ( !, &$ <P!E '(
M2@!E '0 (  U #0       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q 6SCR
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@
M2P   2@          0                         !              $H
M    2P                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M    2P    !29VAT;&]N9P   2@    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   $L     4F=H=&QO
M;F<   $H     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    ".$))300,      W0     0   *     I   !X   3.    VT !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1"  I * # 2(
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M!!S5=Q((%OL22\GS?JK]8^AX+/K&<HLR06V9 8]_K5[RW6VQYVY/N=MR:_\
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M0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ',
M: !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3
M #8    ! #A"24T$(@     !3DU- "H    (  @!$@ #     0 !   !&@ %
M     0   &X!&P %     0   '8!*  #     0 "   !,0 "    '@   'X!
M,@ "    %    )P!.P "    $@   +"':0 $     0   ,0   #P !"=@@
M)Q  $)V"   G$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3@Z
M,#0Z,C0@,#0Z,C(Z,C  5&AO;6%S(%1U8V-I87)O;F4      Z !  ,    !
M__\  * "  0    !   !** #  0    !    2P         & 0,  P    $
M!@   1H !0    $   $^ 1L !0    $   %& 2@  P    $  @   @$ !
M  $   %. @( !     $              $@    !    2     $X0DE- _T
M      @          /_A 5!-30 J    "  ( 1(  P    $      1H !0
M  $   !N 1L !0    $   !V 2@  P    $  @   3$  @   !X   !^ 3(
M @   !0   "< 3L  @   !(   "PAVD !     $   #$    \    \     !
M   #P     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$X.C T
M.C(T(# T.C(R.C(P %1H;VUA<R!4=6-C:6%R;VYE      .@ 0 #     ?__
M  "@ @ $     0   2B@ P $     0   $L         !@$#  ,    !  8
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M 0$! 0$! 0$!_\  $0@ 0@$% P$1  (1 0,1 ?_$ !\   (" @,! 0$
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M&84+>RF7+1*?^-UYX\Z]%M;O4=OS3>W[;2V8;5MI,FH+8*EO+BAQ&WO,-JK
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M2M8]R-^ZE_ABZR2W8.SS[2*M2LK6>5^+RBHECF]+.JX8Q(L=#.2N>W%6 /\
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M=V):EVD'&=KM##+$K>W$C#/!.JK+ZBV".78HK9HPVWOQTZA#@X)59)(Y"/\
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M*&*-J,CBBC8C61QQL:C&,8B-:U$:U$1$3K(A)))))).23R23Y)/N3K3(
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MZ>_XJ?[2;97E$_[2M=_G_P"">/"_G\?Y_LGA?Z^?'6G?3')Z3I /^\U>1_\
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M)GUX;3AABC"DOZ^0^ 24+)XEJ;EB^G/4=!8KC-2W*%8Q=&BC2Y G\!E/R0S
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MF=2R3A5QIHCB3LS0FP<%S 39U1G->[$[G!]BUA&'UN(EF 7-P=G;\E6VK2;
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;HT:.C1HZ-&CHT:.C1HZ-&CHT:.C1HZ-&O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g573964g85h57.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g573964g85h57.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1C:4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      $_    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    N %P 7 !0 $@ 6 !& $( 50 M $T 5P!% "T 1@!0
M #$ ,  N &8 :0!N &, ;P!A &0 +@!C &\ ;0!< $$ 6@ P #$ -0 Q "T
M6 !% %( 3P!8 "T ,0 X       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'D
M           *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P     $  0/
M     0 !.$))300F       .             #^    X0DE-! T       0
M   >.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M   ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    !
M "T    &       !.$))30/X      !P  #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M #A"24T$"       $     $   )    "0      X0DE-!!X       0
M.$))300:      ,U    !@              YP   Z4          0
M                   !              .E    YP
M   !                         !     !        ;G5L;     (    &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG    YP    !29VAT;&]N9P
M Z4    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@
M  =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I
M;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP
M965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   .<     4F=H=&QO;F<   .E     W5R;%1%6%0
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M;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M   *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M    "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M    .$))3001       ! 0 X0DE-!!0       0    #.$))300,      YV
M     0   *     H   !X   2P    Y: !@  ?_8_^T #$%D;V)E7T--  +_
M[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5
M$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.
M#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,
M# P,# P,# P,# P,# S_P  1"  H * # 2(  A$! Q$!_]T !  *_\0!/P
M 04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !
M  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!
M,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?2
M5>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'
MEZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "$0,A,1($05%A<2(3!3*!D12A
ML4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+R
MLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'
M_]H # ,!  (1 Q$ /P WUM^LO6NJ==LZ)TJRRJFJ[[,RJEWIONN'LM]6T%NV
MIK][-GJ>EL9ZUW_!C?\ XMOK376;V78[[@-WILML%A/[K;GUL;O_ *ST3ZV_
M5GK?3.NV]:Z57;;3;;]I9;0WU+*;3[K?4I <YU6_>_?Z?I>F_P!*[_A!X_\
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MXQO_  O\Y^B5?)_Q7=3PL;[9@9C+LR@>H*JV.I=+?=^K9+;'N]7_ $>YE?\
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M7E'2F[?JMUUI[/Z</_!+EUF%_BFQZ[P_,Z@;:1S714*G.^-KK+]O]EBM8O\
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M %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\
M<P!H &\ <  @ $, 4P V     0 X0DE-!"(      2Y-30 J    "  ' 1(
M P    $  0   1H !0    $   !B 1L !0    $   !J 2@  P    $  @
M 3$  @   !X   !R 3(  @   !0   "0AVD !     $   "D    T  ]"0
M "<0 #T)    )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$W
M.C U.C(V(# Y.C4X.C(T   #H $  P    '__P  H ( !     $   .EH ,
M!     $   #G          8! P #     0 &   !&@ %     0   1X!&P %
M     0   28!*  #     0 "   " 0 $     0   2X" @ $     0
M        2     $   !(     3A"24T#_0      "      !    _^$!,$U-
M "H    (  <!$@ #     0     !&@ %     0   &(!&P %     0   &H!
M*  #     0 "   !,0 "    '@   '(!,@ "    %    )"':0 $     0
M *0   #0   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I
M;F1O=W,I #(P,3<Z,#4Z,C8@,#DZ-3@Z,C0   .@ 0 #     ?__  "@ @ $
M     0   Z6@ P $     0   .<         !@$#  ,    !  8   $:  4
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  W . # 1$
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MFL/4LGX6_3.QY-K;6164I&PIS'B:6-X"QB6+-2Y(A6TMAF8?C"\UO9OMA?\
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M4K05<ZG</ U6P,-K9J:[>/Q#$2U1Q'QZY1/[]^NW>3;8NP>]_E7N.JU3/F3
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M_P"LJJW,)OTC5645W"CG,\%O&T!&N)X\U"8P)$R2[G??3^/#&XO4"*Z47HR
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M#B5-7A-C)GG*=#(4O$QEXESSD(QXRXDRRY^[G]";+/I,389D&B0UL:T[S9]
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MLESCD>$0,!,\V )*<>#?_.]W4_Y<?9/_ *QK3TR7>#^*]*_E_P"G."_W-_\
MZ_YSTNO9W^,=5?V-RO\ OJG]?Q_5']77<?IF_P#3QV?_ ,*UY_O3TQZY/?\
M_D;CO[1U/S]?Q=E?B/\ G^?73["?RKRG]GW^OW?WQQ__ /?B/^?3*_FM_P!5
M]VQ_V9HG][FO_5!]I_\ O"TU_I%S_AMWJ^.YW\@M2_Z"'_Y5?JI+Z6S_ ,#]
MRO\ :O2G_2-E>K+_ $B/\<TM_HV6_P![0ZK/]'S_ !#4W^F8W_<V^I!_4U_Z
M$.H?^*"K?W7;;_\ W_SZXGZ/_P#*_)_V=L_\1Q?7<[\?R/HS^[4%3\]I_P 1
MR7Y_]?EMU4J#HVP;@^G7766L D,3]$=K+9MYJ*)%E.5G41HFE*L\^,>'/O\
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M^XNK+0/S,7*R]MRO:@M--PC/W2"JS&,MR4[^@D$K@O1L7[F)N^&'QL]V>O\
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M7-DVA9JMOVKVYQ6ZD)^R?1UW"C[#K\[,15AGP6PB&:/E4),0$9!,,17)F</
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M#9L]6V!JZ6H4YCIGBBQU_LJY+/EP#"?BQ&>-$F4LY(WX\LH.9IX<83R8M0,
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-2VY,,V'.Y,,CDBG_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
